triazoles has been researched along with sitagliptin phosphate in 739 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 188 (25.44) | 29.6817 |
| 2010's | 550 (74.42) | 24.3611 |
| 2020's | 1 (0.14) | 2.80 |
| Authors | Studies |
|---|---|
| Beconi, M; Eiermann, GJ; Fisher, MH; He, H; Hickey, GJ; Kim, D; Kowalchick, JE; Leiting, B; Lyons, K; Marsilio, F; McCann, ME; Patel, RA; Patel, SB; Petrov, A; Roy, RS; Scapin, G; Thornberry, NA; Wang, L; Weber, AE; Wu, JK; Wyvratt, MJ; Zhang, BB; Zhu, L | 1 |
| Deacon, CF | 2 |
| Erlich, R | 1 |
| Bergman, A; Davies, MJ; De Smet, M; Gottesdiener, KM; Herman, GA; Hilliard, D; Musson, D; Ramael, S; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Van Dyck, K; Wagner, JA; Wang, AQ; Winchell, G; Yi, B; Zeng, W | 1 |
| Bergman, AJ; Chen, L; Davies, MJ; De Smet, M; Herman, GA; Hilliard, D; Laethem, M; Ramael, S; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Wagner, JA; Wang, AQ; Winchell, G; Yi, B; Zeng, W; Zhou, Y | 1 |
| Fisher, AL; Musson, DG; Wang, AQ; Zeng, W | 1 |
| Heinzl, S | 2 |
| Feng, Y; Howard, AD; Li, C; Li, Z; Moller, DE; Mu, J; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
| Bergman, A; Blum, R; Chen, L; Dilzer, S; Herman, GA; Hilliard, D; Lasseter, K; Liu, F; Meehan, AG; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Wagner, JA; Wang, AQ; Zeng, W | 1 |
| Jago, C | 1 |
| Bergman, A; Cilissen, C; Davies, MJ; de Lepeleire, I; De Smet, M; Deacon, CF; Dietrich, B; Golor, G; Gottesdiener, KM; Herman, GA; Hilliard, D; Holst, JJ; Keymeulen, B; Kipnes, MS; Kotey, P; Lasseter, KC; Schrodter, A; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Van Dyck, K; Wagner, JA; Wang, AQ; Yi, B; Zeng, W; Zhao, P | 1 |
| Warpakowski, A | 1 |
| Faidley, TD; Hickey, GJ; Leiting, B; Lyons, K; Pryor, KD; Thompson, DR | 1 |
| Caria, C; Hanefeld, M; Khatami, H; Raz, I; Williams-Herman, D; Xu, L | 1 |
| Bergman, A; Herman, GA; Kipnes, M; Yi, B | 1 |
| Biftu, T; Eiermann, G; Feng, D; Gao, YD; He, H; Kieczykowski, G; Leiting, B; Liang, GB; Lyons, K; Patel, S; Petrov, A; Qian, X; Scapin, G; Singh, S; Sinha-Roy, R; Thornberry, NA; Weber, AE; Wu, J; Zhang, B; Zhang, X | 1 |
| Barnett, A | 1 |
| Drucker, DJ; Nauck, MA | 1 |
| Booth, SW; Fitzpatrick, S; Newton, MJ; Taylor, S | 1 |
| Traynor, K | 1 |
| Aschner, P; Kipnes, MS; Lunceford, JK; Mickel, C; Sanchez, M; Williams-Herman, DE | 1 |
| Charbonnel, B; Karasik, A; Liu, J; Meininger, G; Wu, M | 1 |
| Sanchez, M; Scott, R; Stein, P; Wu, M | 1 |
| Andryuk, PJ; Brazg, R; Lu, K; Rosenstock, J; Stein, P | 1 |
| Bailey, CJ; Flatt, PR; Green, BD | 3 |
| Bergman, AJ; Chen, L; Dilzer, S; Ebel, D; Elmore, CS; Gottesdiener, K; Herman, GA; Larson, P; Lasseter, K; Reed, JR; Vincent, SH; Wagner, JA; Xu, S; Zeng, W; Zhu, B | 1 |
| Arison, BH; Kim, D; Liu, DQ; Stearns, RA; Vincent, SH | 1 |
| Beconi, MG; Ciccotto, S; Elmore, CS; Hora, DF; Kochansky, CJ; Liu, DQ; Reed, JR; Stearns, RA; Teffera, Y; Vincent, SH; Xia, YQ; Xu, S | 1 |
| Bergman, AJ; Cilissen, C; Davies, MJ; Gottesdiener, KM; Haazen, W; Herman, GA; Luo, WL; Mistry, GC; Wagner, JA | 1 |
| Bergman, A; Chen, L; Cote, J; Dilzer, S; Herman, G; Krishna, R; Larson, P; Lasseter, K; Wagner, J; Wang, A; Zeng, W | 1 |
| Nathan, DM | 1 |
| Brazg, R; Cobelli, C; Dalla Man, C; Stein, PP; Thomas, K; Xu, L | 1 |
| Meininger, G; Nauck, MA; Sheng, D; Stein, PP; Terranella, L | 1 |
| Bergman, AJ; Bleasby, K; Braun, MP; Cai, X; Chan, GH; Chu, XY; Dean, DC; Evers, R; Hafey, MJ; Xu, S; Yabut, J | 1 |
| Gallwitz, B | 6 |
| Ahrén, B | 5 |
| Drucker, D; Easley, C; Kirkpatrick, P | 1 |
| Campbell, KM; Taylor, JR | 1 |
| Lyseng-Williamson, KA | 1 |
| Kipnes, MS | 1 |
| Raz, I | 1 |
| Thornberry, NA; Weber, AE | 1 |
| Winkler, G | 1 |
| Herman, GA; Stein, PP; Thornberry, NA; Wagner, JA | 1 |
| Pratley, RE; Salsali, A | 1 |
| Becker, JW; Biftu, T; Doss, GA; Eiermann, G; Feng, D; He, H; Lyons, K; Patel, S; Petrov, A; Scapin, G; Singh, S; Sinha-Roy, R; Thornberry, NA; Weber, AE; Wu, J; Zhang, B; Zhang, X | 1 |
| Edmondson, SD; Eiermann, GJ; He, H; Kim, D; Kowalchick, JE; Leiting, B; Lyons, KA; Mastracchio, A; Patel, RA; Pryor, KD; Thornberry, NA; Weber, AE; Wu, JK; Xu, J | 1 |
| Bergman, AJ; Cote, J; Gottesdiener, K; Herman, GA; Marbury, T; Smith, W; Swan, SK; Wagner, J; Yi, B | 1 |
| Feinglos, MN; Goldstein, BJ; Johnson, J; Lunceford, JK; Williams-Herman, DE | 1 |
| Bloomgarden, ZT; Inzucchi, SE | 1 |
| Mintz, ML | 1 |
| Irony, I; Meyer, RJ; Parks, MH | 1 |
| Eldor, R; Raz, I | 1 |
| Klein, HH; Meier, JJ; Schmidt, WE | 1 |
| Hanefeld, M; Herman, GA; Mickel, C; Sanchez, M; Stein, PP; Wu, M | 1 |
| Scheen, AJ | 8 |
| Bergman, A; Chen, L; Dilzer, S; Herman, GA; Krishna, R; Lasseter, K; Liu, Q; Luo, WL; Mistry, GC; Stone, J; Wagner, JA; Wang, A; Zeng, W | 1 |
| Bergman, A; Chen, L; Dilzer, S; Ebel, D; Herman, G; Krishna, R; Lasseter, K; Liu, F; Stone, J; Wagner, J; Wang, A; Zeng, W | 1 |
| Fanurik, D; Hermansen, K; Khatami, H; Kipnes, M; Luo, E; Stein, P | 1 |
| Amori, RE; Lau, J; Pittas, AG | 1 |
| Jennings, HR; Langley, AK; Suffoletta, TJ | 1 |
| Whitehill, D | 1 |
| Mirza, SA | 1 |
| Dailey, GE | 1 |
| Singer, M | 1 |
| Heinzl, S; Musch, A | 1 |
| Kast, RE | 1 |
| Ahmed, T; Davies, MJ; Fujimoto, G; Hirayama, Y; Kakikawa, T; Kato, N; Nonaka, K; Okuyama, K; Sato, A; Stein, PP; Suzuki, H | 1 |
| Aleti, R; Boggavarapu, R; Kandikere, V; Komarneni, P; Mudigonda, K; Nirogi, R | 1 |
| Krska, SW; Shultz, CS | 1 |
| Perusicová, J | 1 |
| Chen, L; Fisher, AL; Musson, DG; Schwartz, MS; Wang, AQ; Woolf, EJ; Zeng, W | 1 |
| Aschner, P; Davies, MJ; Karasik, A; Katzeff, H; Stein, PP | 1 |
| Alba, M; Amatruda, JM; Chen, Y; Hussain, S; Kaufman, KD; Langdon, RB; Raz, I; Stein, PP; Wu, M | 1 |
| Davies, MJ; Engel, SS; Loeys, T; Scott, R | 1 |
| Pyon, EY; Zerilli, T | 1 |
| Doudet, DJ; Kim, SJ; McIntosh, CH; Nian, C | 2 |
| Nogid, A; Pham, DQ; Plakogiannis, R | 1 |
| Davies, MJ; Gottesdiener, KM; Herman, GA; Lasseter, KC; Maes, AL; Mistry, GC; Wagner, JA | 1 |
| Scheen, AJ; Van Gaal, LF | 3 |
| Bandeira-Echtler, E; Bergerhoff, K; Lerch, CL; Richter, B | 1 |
| Alemao, E; Chen, J; Cook, J; Gouveia, M; Jameson, K; Krishnarajah, G; Nocea, G; Schwarz, B; Sintonen, H; Yin, D | 1 |
| Jackson, EK; Mi, Z | 1 |
| Hussar, DA | 1 |
| Charbonnel, B; Cobelli, C; Davies, MJ; Man, CD; Meninger, G; Stein, PP; Williams-Herman, D; Xu, L | 1 |
| Duh, D; Vandevijver, A | 1 |
| Mikhail, N | 2 |
| Erol, A | 1 |
| Choe, HM; Sweet, BV; VanDeKoppel, S | 1 |
| Bergman, AJ; Gottesdiener, KM; Herman, GA; Hreniuk, D; Mistry, GC; Ruddy, M; Wagner, JA; Zheng, W; Zinny, MA | 1 |
| Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H | 1 |
| Benedetti, E; Focosi, D; Galimberti, S; Kast, RE; Metelli, MR; Papineschi, F; Petrini, M | 1 |
| Arellano, S; Di Girolamo, G; Gagliardino, JJ; Santoro, S | 1 |
| Amatruda, JM; Arjona Ferreira, JC; Chan, JC; Davies, MJ; Gonzalez, E; Kaufman, KD; Scott, R; Sheng, D; Stein, PP; Williams-Herman, D | 1 |
| Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Elisaf, MS; Florentin, M; Liberopoulos, EN; Mikhailidis, DP | 1 |
| Chawla, PS; Kochar, MS | 1 |
| Pei, Z | 1 |
| Gadsby, R | 1 |
| Doupis, J; Veves, A | 1 |
| Herman, G; Krishna, R; Wagner, JA | 1 |
| Bunck, MC; Diamant, M | 1 |
| De Meester, I; Lambeir, AM; Scharpé, S | 1 |
| DeFronzo, RA; Guan, X; Holcombe, JH; MacConell, L; Okerson, T; Viswanathan, P | 1 |
| Krout, MR; Mohr, JT; Stoltz, BM | 1 |
| Drucker, DJ; Duez, H; Giacca, A; Lewis, GF; Smith, AC; Szeto, L; Xiao, C | 1 |
| Campbell, RK; Neumiller, JJ; Reynolds, JK | 1 |
| Davidson, JA; Gross, JL; Parente, EB | 1 |
| Faust, M; Matthes, J | 1 |
| Fonseca, VA; John-Kalarickal, J; Wani, JH | 1 |
| Ahn, JH; Bae, MA; Cheon, HG; Jun, MA; Kang, NS; Kang, SK; Kim, KR; Kim, KY; Kim, SG; Kim, SS; Kim, SY; Lee, DH; Lee, JO; Park, WS; Rhee, SD; Shin, MS; Sohn, SK | 1 |
| Taéron, C | 1 |
| Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E | 1 |
| Seissler, J | 1 |
| Kao, DP; Kohrt, HE; Kugler, J | 1 |
| Kao, DP | 1 |
| Feinglos, M; Green, J | 1 |
| Bandeira-Echtler, E; Bergerhoff, K; Lerch, C; Richter, B | 1 |
| Egan, JM; Kim, W | 1 |
| Amatruda, JM; Kaufman, KD; Langdon, RB; Mohan, V; Noble, L; Son, HY; Stein, PP; Xu, L; Yang, W | 1 |
| Gupta, R; Pal, M; Parsa, KV; Singh, SK; Tokala, RK; Walunj, SS | 1 |
| Siddiqui, NI | 1 |
| Augustyns, K; Chen, X; De Cock, H; De Meester, I; Dubois, V; Lambeir, AM; Scharpé, S; Van der Veken, P; Van Ginneken, C | 1 |
| Bergman, AJ; Cote, J; Davies, MJ; De Smet, M; Herman, GA; Keymeulen, B; Laethem, T; Maes, A; Mathijs, Z; Roadcap, BA; Sun, L; Valesky, RJ; Wagner, JA; Yang, A; Zhao, JJ | 1 |
| Boye, KS; Fabunmi, R; Lage, MJ; Misurski, DA | 1 |
| Bergman, AJ; Davies, MJ; Dilzer, SC; Herman, GA; Lasseter, KC; Luo, WL; Migoya, EM; Stevens, CH; Wagner, JA | 1 |
| Amatruda, JM; Davies, MJ; Goldstein, BJ; Johnson, J; Kaufman, KD; Luo, E; Teng, R; Williams-Herman, D | 1 |
| Gallen, IW; Lumb, AN | 1 |
| Boucher, BJ | 1 |
| DiGregorio, RV; Pasikhova, Y | 1 |
| Amatruda, JM; Fukao, Y; Johnson-Levonas, AO; Nonaka, K; Okuyama, K; Tsubouchi, H | 1 |
| Argyrakopoulou, G; Doupis, J | 1 |
| Nicolucci, A; Rossi, MC | 1 |
| Kripke, C | 1 |
| Arnold Chan, K; Dore, DD; Seeger, JD | 1 |
| East, HE; Riche, DM; Riche, KD | 1 |
| Butler, AE; Butler, PC; Cox, HI; Dry, S; Galasso, R; Gurlo, T; Matveyenko, AV; Moshtaghian, A | 1 |
| Alves, G; Bigni, R; de Andrade, CF; Pereira, DA; Pombo-de-Oliveira, MS | 1 |
| Miuchi, M; Miyagawa, J; Nanba, M | 1 |
| Arjona Ferreira, JC; Horie, Y; Kanazu, S; Narukawa, M; Nonaka, K; Takeuchi, M; Taniguchi, T | 1 |
| Armstrong, JD; Balsells, J; Clausen, A; Grabowski, EJ; Hansen, KB; Hsiao, Y; Ikemoto, N; Krska, S; Kubryk, M; Malan, C; Rivera, N; Rosner, T; Simmons, B; Spindler, F; Sun, Y; Xu, F | 1 |
| Cox, JM; Edmondson, SD; Eiermann, GJ; He, H; Lyons, KA; Mastracchio, A; Patel, RA; Patel, SB; Petrov, A; Roy, RS; Scapin, G; Thornberry, NA; Weber, AE; Wu, JK; Xu, S; Zhu, B | 1 |
| Keating, N | 1 |
| Bergman, AJ; Bloomfield, DM; Ghosh, K; Gottesdiener, KM; Gutierrez, MJ; Herman, GA; Hickey, L; Hreniuk, D; Krishna, R; Miller, J; Stoltz, R; Wagner, JA | 1 |
| Alexander, CM; Chapell, R; Gould, AL | 1 |
| Cognard, E; Shepherd, PR; Smith, GC; Vickers, MH | 1 |
| Giampietro, O; Matteucci, E | 1 |
| Alba, M; Goldstein, BJ; Guan, Y; Herman, G; Kaufman, KD; Larson, P; Sachs, JR; Sheng, D; Thornberry, N; Williams-Herman, D | 1 |
| Cross, LB; Gentry, C; Gross, B; McFarland, MS; Patel, UP; Tunney, J | 1 |
| Gallwitz, B; Thornberry, NA | 1 |
| Eiermann, GJ; Feng, Y; Howard, AD; Li, C; Li, Z; Mu, J; Petrov, A; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
| Drucker, DJ; Hansotia, T; Longuet, C; Maida, A; Seino, Y | 1 |
| Herman, GA; Johnson-Levonas, AO; Liu, Q; Maes, A; Wagner, JA; Wright, DH | 1 |
| Curtiss, FR; Fairman, KA | 1 |
| Bode, BW | 1 |
| D'Alessio, D; Jessen, L | 1 |
| Kumagai, N; Mashiko, T; Shibasaki, M | 1 |
| Matthaei, S | 1 |
| Bischoff, A | 1 |
| Barnett, AH; Palalau, AI; Piya, MK; Tahrani, AA | 1 |
| Freeman, JS | 2 |
| Henson, K; Hight, R; Welborn, D; Wyatt, S | 1 |
| Abbatecola, AM; D'Amico, M; Di Filippo, C; Ferraraccio, F; Marfella, R; Paolisso, G; Rossi, F | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Schubert-Zsilavecz, M; Steinhilber, D; Zettl, H | 1 |
| Basu, R; Bock, G; Cobelli, C; Dalla Man, C; Deacon, CF; Giesler, PD; Holst, JJ; Laugen, J; Micheletto, F; Rizza, RA; Toffolo, G; Vella, A | 1 |
| Alexander, CM; Siler, SQ; Topp, BG; Waters, SB | 1 |
| Brenner, C; Engelmann, MG; Franz, WM; Henschel, V; Huber, B; Mansmann, U; Reiser, M; Steinbeck, G; Theiss, HD; Wintersperger, B; Zaruba, MM | 1 |
| Hoerger, T; Pogach, L; Rajan, M; Sinha, A | 1 |
| Aschner, P; Goldstein, BJ; Guo, H; Katzeff, HL; Kaufman, KD; Sunga, S; Williams-Herman, D | 1 |
| Dutka, DP; Heck, PM; Hoole, SP; Khan, FZ; Read, PA | 1 |
| Amatruda, JM; Andryuk, PJ; Cefalu, WT; Chen, Y; Engel, SS; Katz, L; Kaufman, KD; Ling, Y; Luo, E; Musser, B; Rosenstock, J; Vilsbøll, T; Yki-Järvinen, H | 1 |
| Fontés, G; Hagman, DK; Latour, MG; Poitout, V; Semache, M | 1 |
| Ban, K; Drucker, DJ; Henkelman, RM; Husain, M; Momen, MA; Sauvé, M; Zhou, YQ | 1 |
| Cross, LB; Foard, J; Gross, BN; Wood, Y | 1 |
| Hsu, CH; Huang, CL; Huang, KC; Su, HY; Weng, SF | 1 |
| Bilkovski, R; Faust, M; Freude, S; Krone, W; Laudes, M; Oberhauser, F; Schilbach, K; Schulte, DM; Schulz, O | 1 |
| Dhillon, S | 1 |
| Peters, A | 1 |
| Birnbaum, Y; Keyes, KT; Lin, Y; Perez-Polo, JR; Ye, Y; Zhang, C | 1 |
| Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S | 1 |
| Amatruda, J; Arjona Ferreira, JC; Iwamoto, Y; Nonaka, K; Okamoto, T; Okuyama, K; Taniguchi, T | 1 |
| Meier, JJ; Menge, BA; Schmidt, WE | 1 |
| Agostini, C; Albiero, M; Avogaro, A; Boscaro, E; de Kreutzenberg, S; Fadini, GP; Frison, V; Menegazzo, L; Tiengo, A | 1 |
| Kim, SJ; McIntosh, CH; Nian, C | 1 |
| Bilan, VP; Jackson, EK; Tofovic, DS | 1 |
| Aaboe, K; Deacon, CF; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T | 1 |
| Cefalu, WT | 1 |
| Clay, RJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Machotka, SV; Williams-Herman, DE | 1 |
| Aguila, MB; Cardoso-de-Lemos, FS; de Carvalho, L; Gregório, BM; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Amatruda, JM; Goldstein, BJ; Golm, G; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D | 1 |
| Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Montanya, E; Nauck, M; Pratley, RE; Søndergaard, RE; Thomsen, AB | 1 |
| Amatruda, JM; Davies, MJ; Kaufman, KD; Nauck, M; Seck, T; Sheng, D; Stein, PP; Sunga, S | 1 |
| Berria, R; Davis, KL; Horton, ES; Silberman, C | 1 |
| Davies, MJ; Engel, SS; Mavros, P; Radican, L; Rajagopalan, S; Yin, D; Zhang, Q | 2 |
| Guerci, B; Halter, C | 1 |
| Abel, T; Fehér, J | 1 |
| Aoki, K; Masuda, K; Miyazaki, T; Terauchi, Y; Togashi, Y | 1 |
| Garg, R; Hussey, C; Ibrahim, S | 1 |
| Baudrant, M; Benhamou, PY; Halimi, S; Lablanche, S; Skalli, S; Wion-Barbot, N | 1 |
| Unger, J | 1 |
| Brands, J; Colbeck, JC; Devine, PN; Fleitz, FJ; Hughes, GJ; Huisman, GW; Janey, JM; Jarvis, WR; Krebber, A; Moore, JC; Mundorff, EC; Savile, CK; Tam, S | 1 |
| Kuritzky, L | 1 |
| Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P | 1 |
| Meier, JJ; Nauck, MA | 1 |
| Amatruda, JM; Arjona Ferreira, JC; Iwamoto, Y; Kadowaki, T; Nishii, M; Nonaka, K; Tajima, N; Taniguchi, T | 1 |
| Constanzer, M; Woolf, EJ; Xu, Y; Zeng, W | 1 |
| Fakhoury, WK; Lereun, C; Wright, D | 1 |
| Brinker, A; Desai, S; Iyasu, S; Swann, J | 1 |
| Svec, F | 1 |
| Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N | 1 |
| Lutz, S | 1 |
| Fernandes, R; Ferreira, L; Garrido, P; Mega, C; Melo, A; Nunes, S; Parada, B; Pinto, F; Pinto, R; Reis, F; Santos, P; Sereno, J; Teixeira, F; Teixeira-de-Lemos, E; Vala, H; Velada, I | 1 |
| Jackson, EK | 1 |
| Brown, NJ; Byrne, L; Kunchakarra, S; Marney, A | 1 |
| Chen, W; Garg, R; Pendergrass, M | 1 |
| Yanai, H | 1 |
| Gerich, J | 1 |
| Bergman, BC; Cobelli, C; Hunerdosse, DM; Man, CD; Perreault, L | 1 |
| Bhalodia, Y; Manek, R; Sheth, N; Vaghasiya, J | 1 |
| Borelli, MI; Del Zotto, H; Flores, LE; Francini, F; Gagliardino, JJ; Madrid, VG; Maiztegui, B; Massa, ML; Raschia, MA; Rebolledo, OR | 1 |
| Garber, AJ | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
| Charpentier, G; Gause-Nilsson, I; Hellqvist, A; Ostgren, CJ; Scheen, AJ | 1 |
| Ahn, SH; Bae, MA; Choi, MK; Jin, QR; Song, IS | 1 |
| Opsteen, C; Qi, Y; Retnakaran, R; Vivero, E; Zinman, B | 1 |
| Gottesdiener, KM; Gutierrez, M; Johnson-Levonas, AO; Liu, Q; Matthews, CZ; Migoya, EM; Miller, JL; Wagner, JA; Zheng, W | 1 |
| Alexander, CM; Cai, B; Girman, CJ; Katz, L; Williams-Herman, D | 1 |
| Caputo, S; Ghirlanda, G; Martini, F; Musella, T; Pitocco, D; Scavone, G; Zaccardi, F | 1 |
| Coben, J; Dobrian, AD; Galkina, EV; Leone, KA; Lindsay, JW; Ma, K; Ma, Q; Nadler, JL | 1 |
| Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W | 1 |
| Couto, GK; Crajoinas, RO; Davel, AP; Girardi, AC; Lessa, LM; Pacheco, BP; Rossoni, LV | 1 |
| Anjana, RM; Kishore, U; Mohan, V; Sudhakaran, C; Unnikrishnan, R | 1 |
| Baggio, LL; Drucker, DJ; Grynpas, MD; Kyle, KA; Willett, TL | 1 |
| Augustyns, K; Baerts, L; De Keulenaer, G; De Meester, I; De Meyer, G; Dubois, V; Matheeussen, V; Scharpé, S; Van der Veken, P | 1 |
| Appenzeller, M; Bigliardi, P; Buclin, T; Grouzmann, E; Pannatier, A | 1 |
| Arechavaleta, R; Chen, Y; Duran, L; Goldstein, BJ; Kaufman, KD; Krobot, KJ; O'Neill, EA; Seck, T; Williams-Herman, D | 1 |
| Hollander, P; Liutkus, JF; Raslova, K; Råstam, J; Skjøth, TV | 1 |
| Hattori, S | 1 |
| Bergman, A; Johnson-Levonas, AO; Larson, P; Lasseter, KC; Migoya, E; Miller, J; Wagner, JA | 1 |
| Couture, P; Deacon, CF; Lamarche, B; Tremblay, AJ; Weisnagel, SJ | 2 |
| Amatruda, JM; Golm, GT; Kaufman, KD; Meehan, AG; Shockey, GR; Steinberg, H; Teng, R; Thakkar, PR; Williams-Herman, DE; Yoon, KH | 1 |
| Acuña, C | 1 |
| Boudes, P; Viereck, C | 1 |
| Best, JH; Garrison, LP; Li, Y; Malloy, J; Peyrot, M; Rubin, RR; Yan, P | 1 |
| Desai, AA | 1 |
| Bergman, AJ; Chen, L; Davies, MJ; Gottesdiener, KM; Herman, GA; Langdon, RB; Larson, PJ; Mistry, GC; Ruckle, JL; Snyder, K; Wagner, JA; Wang, AQ; Yi, B; Zeng, W | 1 |
| Seyoum, B | 1 |
| Jellinger, PS | 1 |
| Ishiki, M; Ito, S; Mori, T; Nako, K; Ogawa, S; Okamura, M; Senda, M | 1 |
| Cuddihy, R; Davies, M; Hammer, M; Pratley, R; Thomsen, AB | 1 |
| Chwieduk, CM | 1 |
| Butler, PC; Elashoff, M; Elashoff, R; Gier, B; Matveyenko, AV | 1 |
| Choi, SE; Han, SJ; Jung, JG; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Yi, SA | 1 |
| Chen, B; Ernsberger, P; Escobedo, LV; Hou, D; Koletsky, MS; Koletsky, RJ; Moore, A | 1 |
| Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Garber, A; Hartvig, H; Montanya, E; Nauck, M; Pratley, R; Thomsen, AB | 1 |
| Nader, MA | 2 |
| Spellman, CW | 1 |
| Chen, M; Goldstein, BJ; Johnson-Levonas, AO; Kaufman, KD; Olansky, L; Reasner, C; Seck, TL; Terranella, L; Williams-Herman, DE | 1 |
| Amatruda, JM; Barzilai, N; Caporossi, S; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Langdon, RB; Mahoney, EM; Steinberg, H; Williams-Herman, D | 1 |
| Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P | 1 |
| Denn, M; Gallagher, RT; Peter, RM; Swales, JG | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Daniela, L; Ludvik, B | 1 |
| Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Seck, TL; Sisk, CM; Wang, H; Williams-Herman, DE | 1 |
| Hawkes, N | 1 |
| Matsuura, K; Mori, Y; Sezaki, K; Taniguchi, Y; Utsunomiya, K; Yokoyama, J | 1 |
| Hibi, T; Kaneko, F; Motoori, T; Oda, M; Ohbu, M; Shimizu, Y; Tahara, K; Takeuchi, H; Toyoda-Akui, M; Yokomori, H | 1 |
| Doggrell, SA | 1 |
| Chen, M; Goldstein, BJ; Kaufman, KD; Mehta, A; Olansky, L; Reasner, C; Seck, TL; Terranella, L; Williams-Herman, DE | 1 |
| Dunn, PJ | 1 |
| Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R | 1 |
| Chisholm, DJ; Douglas, A; Greenfield, JR; Gribble, FM; Holst, JJ; Piyaratna, N; Samocha-Bonet, D; Synnott, EL; Wong, O | 1 |
| Kondo, M; Tanizawa, Y | 1 |
| Aguila, MB; da Silva Faria, T; Gregório, BM; Mandarim-de-Lacerda, CA; Relvas-Lucas, B; Souza-Mello, V | 1 |
| Ringenberg, MR; Ward, TR | 1 |
| Amo, K; Ito, Y; Koganei, M; Ohminami, H; Orime, K; Sasaki, H; Shirakawa, J; Tajima, K; Takeda, E; Terauchi, Y; Togashi, Y | 1 |
| Berg, JK; Gray, AL; Heilmann, CR; Holcombe, JH; Shenouda, SK | 1 |
| Hibi, H; Ohori, T; Yamada, Y | 1 |
| Ayoub, BM; El-Bagary, RI; Elkady, EF | 1 |
| Kipnes, M; Subbarayan, S | 1 |
| Elahi, D; Meneilly, GS; Stafford, S | 1 |
| Armanet, M; Burcelin, R; Cabou, C; Castel, J; Cattan, P; Drucker, DJ; Garret, C; Holst, JJ; Karaca, M; Magnan, C; Maida, A; Masseboeuf, M; Payros, G; Sulpice, T; Waget, A | 1 |
| Koelling, TM; Nemerovski, CW; Pinelli, NR | 1 |
| Gundert-Remy, U; Spranger, J; Stammschulte, T | 1 |
| Khalid, S; Maurya, PK; Rao, RN | 1 |
| Hurren, KM; Pinelli, NR | 1 |
| Jung, HS; Kim, JH; Kim, KW; Kim, SK; Kim, YS; Lee, MK; Lee, MS; No, H; Oh, BJ; Oh, SH; Park, KS | 1 |
| DeYoung, MB; Herbert, P; MacConell, L; Sarin, V; Trautmann, M | 1 |
| Arwert, EN; Driskell, RR; Goldie, SJ; Hoste, E; Mentink, RA; Quist, S; Watt, FM | 1 |
| Fan, L; Gruenberger, JB; Kantor, E; Signorovitch, JE; Swallow, E; Wu, EQ | 1 |
| Baburaj, R; Edwards, CM; Lestner, JM | 1 |
| Engel, SS; Goldstein, BJ; Kaufman, KD; Lee, MA; Pérez-Monteverde, A; Seck, T; Sisk, CM; Williams-Herman, DE; Xu, L | 1 |
| Cander, S; Ersoy, C; Ertürk, E; Gül, CB; Imamoğlu, S; Kırhan, E; Kıyıcı, S; Öz, Ö; Sarandol, E; Sığırlı, D; Tuncel, E; Ünal, OK; Yorulmaz, H | 1 |
| Gibbs, JP; Greene, RJ; Greg Slatter, J; Tu, H | 1 |
| Böhm, M; Kazakov, A; Laufs, U; Lenski, M; Marx, N | 1 |
| Chubb, BD; Davies, MJ; Smith, IC; Valentine, WJ | 1 |
| Jermendy, G | 2 |
| Aoki, K; Kamiyama, H; Masuda, K; Shibuya, M; Terauchi, Y; Yoshimura, K | 1 |
| Akehi, Y; Kobayashi, K; Kodera, T; Kudo, T; Nagaishi, R; Nagasako, H; Nomiyama, T; Takenoshita, H; Terawaki, Y; Urata, H; Yanase, T | 1 |
| Ellis, SL; Garg, SK; Hazenfield, RM; Moser, EG; Rodionova, AS; Snell-Bergeon, JK | 1 |
| Ishibashi, Y; Matsui, T; Takeuchi, M; Yamagishi, S | 1 |
| Al Elq, A; Al Omari, M; Al Sifri, S; Al Tayeb, K; Basiounny, A; Davies, MJ; Echtay, A; Engel, SS; Girman, CJ; Harman-Boehm, I; Kaddaha, G; Katzeff, HL; Mahfouz, AS; Musser, BJ; Ozesen, C; Radican, L; Suryawanshi, S | 1 |
| Ahn, HY; An, JH; Cho, YM; Choi, SH; Jang, HC; Kang, SM; Khang, AR; Lee, Y; Lim, S; Park, KS; Shin, H; Yoon, JW | 1 |
| Ogawa, Y; Shimada, S; Tanaka, K | 1 |
| Béni, S; Hu, WH; Li, H; Noszál, B; Sohajda, T; Szente, L; Zeng, LL | 1 |
| Bhome, R; Penn, H | 1 |
| Li, B; Li, X; Li, Z; Sun, X; Tang, Y; Wen, N; Yu, M; Zhu, L | 1 |
| Baerts, L; Bartunek, J; De Meester, I; Gomez, N; Lybaert, P; Mahmoudabady, M; Matheeussen, V; Mathieu, M; Mc Entee, K; Mendes Da Costa, A; Peace, A; Scharpé, S; Touihri, K; Vanderheyden, M | 1 |
| Davies, MJ; Goldstein, BJ; Golm, GT; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D; Xu, L | 1 |
| Kubota, A; Maeda, H; Matsuba, I; Tanaka, Y; Terauchi, Y | 1 |
| Hashimoto, K; Kumagai, C; Nishioka, T; Shinohara, M; Tanimoto, N | 1 |
| Engel, SS; Goldstein, BJ; Golm, GT; Hussain, S; Katz, L; Kaufman, KD; O'Neill, EA; Wainstein, J; Xu, L | 1 |
| Collier, DS; Haire, CE; Lane, JT; Odegaard, DE; Stevens, RB; Wrenshall, LE | 1 |
| Baranyi, U; De Meester, I; Klaus, C; Korom, S; Matheeussen, V; Pilat, N; Ramsey, H; Schwaiger, E; Wekerle, T | 1 |
| Gerrald, KR; Jonas, DE; Runge, T; Van Scoyoc, E; Wines, RC | 1 |
| Dalvie, D; Smith, DA | 1 |
| Cho, JH; Ham, DS; Kim, ES; Kim, JW; Park, HS; Sun, C; Yeom, JA; Yoon, KH | 1 |
| Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K | 1 |
| Ambrósio, AF; Fernandes, R; Gonçalves, A; Leal, E; Paiva, A; Reis, F; Ribeiro, CF; Teixeira Lemos, E; Teixeira, F | 1 |
| Aso, Y; Hara, K; Haruki, K; Inukai, T; Morita, K; Naruse, R; Ozeki, N; Shibazaki, M; Suetsugu, M; Takebayashi, K; Terasawa, T | 1 |
| Kato, T; Kono, S; Ohki, T; Sasaki, Y; Tajiri, Y; Tanaka, K; Tojikubo, M; Tsuruta, M; Yamada, K | 1 |
| Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B | 1 |
| B, S; Dubala, A; K P, A; K, E; Kucherlapati, VS; M, D; Meda, VS; P R, AV | 1 |
| Masmiquel Comas, L; Nicolau Ramis, J | 1 |
| Brubaker, PL; Grieco, A; Iakoubov, R; Lauffer, LM; Sangle, GV; Trivedi, S | 1 |
| Kishimoto, M; Noda, M | 1 |
| de Lemos, ET; Fernandes, R; Mascarenhas-Melo, F; Mega, C; Oliveira, J; Reis, F; Teixeira, F; Vala, H | 1 |
| Boardman, MK; Chan, M; Cuddihy, RM; González, JG; Hanefeld, M; Kumar, A; Russell-Jones, D; Wolka, AM | 1 |
| Akiyama, E; Fujiwara, Y; Izumiya, Y; Jinnouchi, H; Kaikita, K; Kim-Mitsuyama, S; Konishi, M; Kurokawa, H; Maeda, H; Matsubara, J; Matsui, K; Nakamura, T; Nozaki, T; Ogawa, H; Ohba, K; Sugamura, K; Sugiyama, S; Sumida, H; Takeya, M | 1 |
| Murohara, T | 1 |
| Huh, JW; Jang, M; Kim, DH; Kim, TW; Park, JS; Suh, JH; Yoon, SY | 1 |
| Chen, W; Fenton, C; Haffner, SM; Pendergrass, M | 1 |
| Briand, F; Burcelin, R; Sulpice, T; Thieblemont, Q | 1 |
| Furukawa, S; Kumagi, T; Matsuura, B; Miyake, T; Murakami, M; Murakami, S; Niiya, T; Nishino, K; Onji, M; Ueda, T | 1 |
| Holst, JJ; Liu, MK; Salen, G; Saumoy, M; Shang, Q; Xu, G | 1 |
| Caminal-Montero, L; Coto-Segura, P; Esteve-Martinez, A; Mas-Vidal, A; Santos-Juanes, J | 1 |
| Gambale, JJ; Katz, LB; Rothenberg, PL; Sarich, TC; Stein, PP; Vaccaro, N; Vanapalli, SR; Xi, L | 1 |
| Best, JH; DeYoung, MB; Gaebler, JA; Guillermin, AL; Lloyd, A; Samyshkin, Y | 1 |
| Bachmann, OP; Chan, JY; Lüdemann, J; Oliveira, JH; Reed, VA; Violante, R; Yoon, KH; Yu, MB | 1 |
| Boddu, ND; Cheskin, LJ; Kahan, S; Kumar, AA; Palamaner Subash Shantha, G; Samson, RJ | 1 |
| Hood, AF; Litt, JZ; Rader, RK; Schuman, TP; Stoecker, WV; Stricklin, SM | 1 |
| Nauck, MA | 1 |
| Goldstein, BJ; Golm, GT; Kaufman, KD; Lee, M; O'Neill, EA; Steinberg, H; Teng, R; Yoon, KH | 1 |
| Davies, M; Speight, J | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Rabasseda, X | 1 |
| Choi, SH; Hong, ES; Jang, HC; Kang, SM; Khang, AR; Lim, S; Park, KS; Shin, H; Walford, GA; Yoon, JW | 1 |
| Ahrén, B; Deacon, CF; Mannucci, E | 1 |
| Dorso, C; Hamann, L; Harstad, E; Kirby, MS; Kopcho, L; Langish, R; Locke, G; Marcinkeviciene, J; Shipkova, P; Wang, A | 1 |
| Ahn, BY; Cho, BJ; Choi, SH; Jang, HC; Kang, SM; Kim, YB; Lim, S; Park, HS; Park, KS; Shin, H; Yoon, JW | 1 |
| Berman, S; Efrati, S; Golik, A; Hamad, RA; Koren, S; Peleg, RK; Shemesh-Bar, L; Tirosh, A; Vinker, S | 1 |
| Aono, M; Fukushima, T; Harashima, SI; Inagaki, N; Koizumi, T; Murata, Y; Ogura, M; Seike, M; Tanaka, D; Wang, Y | 1 |
| Lam, SY; Leung, KK; Leung, PS; Liang, J | 1 |
| Burugula, L; Kandhagatla, R; Lodagala, DS; Makula, A; Mullangi, R; Pilli, NR | 1 |
| Capuano, G; Nicolle, LE; Usiskin, K; Ways, K | 1 |
| Cheetham, S; Francis, J; Kirby, M; Poucher, SM; Vickers, SP; Zinker, B | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W | 1 |
| Fukuda, K; Itoh, H; Kawai, T; Matsuhashi, T; Meguro, S; Mogi, S; Sano, M; Suzuki, Y | 1 |
| Nyirjesy, P; Usiskin, K; Ways, K; Zhao, Y | 1 |
| Edgerton, LP; Elmore, LK; Patel, MB; Whalin, LM | 1 |
| Burgmaier, M; Esser, M; Liberman, A; Ludwig, A; Marx, N; Ostertag, R; Vasic, D; Vittone, F; Walcher, D | 1 |
| Alba, M; Engel, SS; Goldstein, BJ; Guan, Y; Johnson-Levonas, AO; Kaufman, KD; Li, Z; Shentu, Y; Yang, W | 1 |
| Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D | 1 |
| Aschner, P; Chan, J; Dain, MP; Echtay, A; Fonseca, V; Owens, DR; Picard, S; Pilorget, V; Wang, E | 1 |
| Diamant, M | 1 |
| Alba, M; Astiarraga, B; Casolaro, A; Chen, Y; Ferrannini, E; Gastaldelli, A; Holst, J; Mari, A; Muscelli, E; Seghieri, G | 1 |
| Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR | 1 |
| Davies, MJ; Ferrante, SA; Goldstein, BJ; Kaufman, KD; Krobot, KJ; Meininger, GE; Seck, T; Williams-Herman, D | 1 |
| Gupta, S | 1 |
| El-Agamy, DS; El-Awady, MS; Nader, MA; Shalaby, AA | 1 |
| Deacon, CF; Horowitz, M; Jones, KL; Nauck, M; Rayner, CK; Stevens, JE | 1 |
| Aravind, SR; Balamurugan, R; Davies, MJ; Engel, SS; Girman, CJ; Gupta, JB; Ismail, SB; Katzeff, HL; Loh, SM; Radican, L; Suryawanshi, S; Wadhwa, T; Wolthers, T | 1 |
| Amatruda, JM; Aschner, P; Chen, Y; Dobs, AS; Duran, L; Ferreira, JC; Goldstein, BJ; Golm, GT; Hill, JS; Horton, ES; Kaufman, KD; Langdon, RB; Umpierrez, GE; Williams-Herman, DE | 1 |
| Abuaysheh, S; Chaudhuri, A; Dandona, P; Dhindsa, S; Ghanim, H; Green, K; Makdissi, A; Vora, M | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Daskiran, M; Dickson, WM; Kozma, CM; Nigam, S; Paris, A; Virdi, NS | 1 |
| Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D | 1 |
| Arafat, T; Idkaidek, N | 1 |
| Chang, NC; Hou, WC; Huang, CY; Huang, PH; Kao, YT; Lee, AW; Lin, CY; Lin, FY; Lin, YW; Morishita, R; Nakagami, H; Ou, KL; Shih, CM; Shyu, KG; Tsao, NW; Wu, SC | 1 |
| Gupta, R; Keshwani, P; Saxena, GN; Srivastava, S | 1 |
| Guo, ZK; Lu, YL; Wu, H; Zhai, HL; Zhou, DQ | 1 |
| Gillespie, DG; Jackson, EK; Kochanek, SJ | 1 |
| Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P | 1 |
| Fontenot, EC; Gosmanov, AR | 1 |
| Langer, J; Lee, WC; Palmer, JL; Samyshkin, Y | 1 |
| Kaneto, H; Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M | 1 |
| Bailey, T; Davies, M; Filetti, S; Furber, S; Garber, AJ; Montanya, E; Nauck, MA; Pratley, RE; Thomsen, AB | 1 |
| Buse, J; Jensen, KH; Niswender, K; Pi-Sunyer, X; Russell-Jones, D; Toft, AD; Zinman, B | 1 |
| Igaki, N; Yokota, K | 1 |
| Ando, K; Irako, T; Nishimura, R; Sakamoto, M; Tsujino, D; Utsunomiya, K | 1 |
| Chen, ZY; Huang, Y; Lam, KS; Lau, CW; Liu, J; Liu, L; Ng, CF; Pu, Y; Tian, XY; Wang, YX; Wong, WT; Xu, A; Xu, G; Yao, X; Zhu, Z | 1 |
| Vella, A | 1 |
| Celikel, CA; Deyneli, O; Duman, DG; Kalayci, C; Yilmaz, Y; Yonal, O | 1 |
| Gahler, RJ; Grover, GJ; Juneja, P; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S | 1 |
| Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H | 1 |
| Kimura, H; Masuda, S; Sato, D; Sato, Y | 2 |
| Liu, XL; Lü, XF; Shao, C; Wang, P; Xiao, XH; Xu, ZR; Yang, WY; Yang, ZJ | 1 |
| Fan, K; Hou, J; Jin, W; Ma, J; Tan, Y; Wu, J; Xiao, W; Yu, B; Zheng, D | 1 |
| Gupta, AK; Kailashiya, J; Kumar, N; Singh, SK; Verma, AK | 1 |
| Advani, A; Advani, SL; Connelly, KA; Gilbert, RE; Thai, K; Yuen, DA; Zhang, Y | 1 |
| Aono, M; Fujita, Y; Harashima, SI; Inagaki, N; Koizumi, T; Murata, Y; Ogura, M; Seike, M; Tanaka, D; Wang, Y; Yamane, S | 1 |
| Chen, M; Guo, Z; Hao, J; Houze, J; Lin, DC; Lopez, E; Luo, J; Ma, Z; Nguyen, K; Rulifson, IC; Tian, B; Tian, L; Tran, T; Wang, Y; Zhang, Y | 1 |
| Hansen, LS; Hare, KJ; Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS; Rosenkilde, MM; Viby, NE | 1 |
| Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K | 1 |
| Bianchi, L; Bonaventura, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D | 1 |
| Fowler, MB; Keu, KV; Quon, A; Tavana, H; Witteles, RM | 1 |
| Crajoinas, RO; Fonseca-Alaniz, MH; Giannocco, G; Girardi, AC; Maciel, RM; Oliveira, KC; Salles, TA; Venturini, G | 1 |
| Brand, T; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ | 1 |
| Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F | 2 |
| Hasegawa, K; Iguchi, A; Kono, S; Nakagawachi, R; Odori, S; Sasaki, Y; Satoh-Asahara, N; Shimatsu, A; Tochiya, M; Wada, H | 1 |
| Drouet, C; Graffin, B; Hosotte, M; Kanny, G; Landy, C; Millot, I; Nadaud, J; Plancade, D; Ragot, C | 1 |
| Anderson, MS; Cerra, M; Li, SX; Luo, WL; Matthews, C; O'Neill, EA; Stoch, SA; Wagner, JA | 1 |
| Mateos, JL; Wajchenberg, BL | 1 |
| Caldeira, EJ; da Silva Faria, AL; da Silva, RE; Dias, MA; Ferreira Junior, RS; Leme, VB; Mâncio, RD; Mayoral, EE | 1 |
| Badole, SL; Bagul, PP; Bodhankar, SL; Coutinho, EC; Ghule, AE; Joshi, AC; Khedkar, VM; Khose, RD; Mahamuni, SP; Raut, CG; Wagh, NK | 1 |
| Ikeda, T; Kirinoki-Ichikawa, S; Kubota, Y; Miyamoto, M; Mizuno, K; Takagi, G; Tanaka, K | 1 |
| Fujimoto, M; Ishibashi, R; Ishikawa, T; Kawamura, H; Kitamoto, T; Kobayashi, K; Okabe, E; Onishi, S; Takemoto, M; Yokote, K | 1 |
| Mahé, E; Sigal, ML; Sin, C | 1 |
| Ae, D; Dear, AE; Hb, L; Hu, Y; Liu, H; Rw, S; Simpson, RW; Y, H | 1 |
| Aldhubiab, BE; Attimard, M; Harsha, S; Khan, TA; Nair, AB; Sangi, S; Shariff, A | 1 |
| Uçaktürk, E | 1 |
| Arjona Ferreira, JC; Barzilai, N; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Marre, M; Sisk, CM | 1 |
| Askov-Hansen, C; Hartmann, B; Henriksen, DB; Holst, JJ; Jeppesen, PB; Lund, P | 1 |
| Goodwin, SR; Laciny, E; Reeds, DN; Royal, M; Struthers, H; Yarasheski, KE | 1 |
| Abonour, R; Broxmeyer, HE; Cornetta, K; Farag, SS; Jones, DR; Messina-Graham, S; Robertson, MJ; Schwartz, J; Secrest, A; Srivastava, S; Strother, RM; Wood, L | 1 |
| Inazumi, T; Kimura, M; Komatsu, Y; Kondo, Y; Nakamura, A; Tajima, K; Takihata, M; Tamura, H; Terauchi, Y; Yamada, M; Yamazaki, S | 1 |
| Davies, MJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Shapiro, D | 1 |
| Berry, D; Berry, S; Chien, J; Gaydos, B; Geiger, MJ; Skrivanek, Z | 1 |
| Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
| Brismar, K; Efendic, S; Hage, C; Lundman, P; Mellbin, L; Rydén, L | 1 |
| Ahrén, B; Alsalim, W; Carr, RD; Mari, A; Ohlsson, L; Pacini, G; Tura, A | 1 |
| Arjona Ferreira, JC; Corry, D; Davies, MJ; Goldstein, BJ; Golm, GT; Gonzalez, EJ; Kaufman, KD; Mogensen, CE; Sloan, L; Xu, L | 1 |
| Bakris, GL; Flynn, C | 1 |
| Bellon, M; Bound, MJ; Horowitz, M; Jones, KL; Rayner, CK; Standfield, SD; Wu, T; Zhao, BR | 1 |
| Baruah, MP; Chaudhury, T; Dharmalingam, M; Sethi, BK | 1 |
| Barbieri, M; Boccardi, V; Esposito, A; Marfella, R; Pansini, A; Paolisso, G; Rizzo, MR | 1 |
| DeRuyter, B; Guo, Z; Holstein, M; Lu, Y; Rabinovitch, A | 1 |
| Kanamori, A; Kubota, A; Maeda, H; Matsuba, I; Tanaka, Y; Terauchi, Y | 1 |
| Akiyama, E; Fujisue, K; Hokimoto, S; Iwashita, S; Jinnouchi, H; Kaikita, K; Kurokawa, H; Maeda, H; Matsubara, J; Ogawa, H; Ohba, K; Sugiyama, S; Yamamoto, E | 1 |
| Satoh, K | 1 |
| Ida, K; Ikeda, H; Katsuno, T; Miyagawa, J; Namba, M | 1 |
| Miyazaki, S; Mori, Y; Taniguchi, Y; Utsunomiya, K; Yokoyama, J | 1 |
| Aquilante, CL; Kosmiski, LA; Predhomme, JA; Sidhom, MS; Wempe, MF | 1 |
| Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F | 2 |
| Gondo, S; Hiwatashi, A; Ikeda, H; Inoue, T; Iwamoto, T; Kodama, K; Kuroki, S; Node, K; Oyama, J; Sakamoto, Y; Shimomura, M; Taguchi, I; Uchida, Y | 1 |
| Banks, P; Ding, ZM; Frazier, K; Freiman, J; Ogbaa, I; Powell, D; Ruff, D; Sands, A; Smith, M; Turnage, A; Zambrowicz, B | 1 |
| Bartola, LD; Giampietro, C; Giampietro, O; Masoni, MC; Matteucci, E | 1 |
| Chang, HY; Clark, JM; Richards, TM; Segal, JB; Singh, S; Weiner, JP | 1 |
| Gale, EA | 1 |
| Cohen, D | 2 |
| Blétry, O; Bouilloud, F; Crickx, E; Kahn, JE; Le Beller, C; Marroun, I; Schoindre, Y; Veyrie, C | 1 |
| Badole, SL; Bagul, PP; Coutinho, EC; Ghule, AE; Jangam, GB; Joshi, AC; Khedkar, VM; Khose, RD; Mahamuni, SP; Raut, CG | 1 |
| Aihara, Y; Douhara, A; Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Noguchi, R; Shirai, Y; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H | 2 |
| Grunberger, G | 1 |
| Hari Kumar, KV; Prusty, P; Shaikh, A | 1 |
| Flessner, MF; St Peter, WL; Weinhandl, ED | 1 |
| Akahoshi, F; Ishii, S; Kadowaki, T; Kishida, H; Miyaguchi, I; Nabeno, M; Tanaka, Y | 1 |
| Cho, JY; Jang, IJ; Kang, D; Kim, BH; Kim, JR; Kim, SE; Lim, KS; Shin, SG; Yoon, SH; Yu, KS | 1 |
| Drake, AJ; Iyer, SN; Mendez, CE; Tanenberg, RJ; West, RL | 1 |
| Dixit, TS; Elased, KM; Lucot, JB; Sharma, AN | 1 |
| Atkinson, M; Butler, AE; Butler, PC; Campbell-Thompson, M; Dawson, DW; Gurlo, T | 1 |
| Ayaori, M; Iizuka, M; Ikewaki, K; Iwakami, N; Komatsu, T; Murakami, T; Nakaya, K; Ogura, M; Sasaki, M; Sato, H; Takase, B; Takiguchi, S; Uto-Kondo, H; Yakushiji, E; Yogo, M | 1 |
| Gavish, D; Gevrielov-Yusim, N; Goldenberg, I; Gottlieb, S; Leibovitz, E; Matetzky, S | 1 |
| Hunt, B; Langer, J; Valentine, WJ | 1 |
| Katznelson, L | 1 |
| Akaslan, SB; Arslan, M; Cakir, N; Degertekin, CK; Toruner, FB; Yilmaz, G | 1 |
| Cusick, T; Fisher, JE; Glantschnig, H; Kimmel, DB; Langdon, RB; Li, Z; Mu, J; Pennypacker, BL; Scott, KR; Shen, X; Zhang, BB | 1 |
| Belal, F; El-Enany, N; Patonay, G; Salim, MM; Walash, M | 1 |
| Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J | 1 |
| Alexander, CM; Brodovicz, KG; Engel, SS; Girman, CJ; Kou, TD; O'Neill, EA; Senderak, M | 1 |
| Ishibashi, S; Kotani, K; Nagashima, S; Okada, K; Osuga, J; Ozaki, K; Takahashi, M; Yagyu, H; Yamazaki, H | 1 |
| Bhargava, A; Del Prato, S; Dharmalingam, M; Garber, AJ; Philis-Tsimikas, A; Rasmussen, S; Satman, I; Skjøth, TV | 1 |
| Adams, J; Cersosimo, E; DeFronzo, RA; Garduno-Garcia, Jde J; Solis-Herrera, C; Triplitt, C | 1 |
| Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L | 1 |
| Asche, CV; Eurich, DT; McAlister, FA; Sandhu-Minhas, JK; Senthilselvan, A; Simpson, S | 1 |
| Ahn, SY; Chae, DW; Chin, HJ; Han, JS; Joo, KW; Kim, S; Lee, J; Na, KY | 1 |
| Ardestani, A; Dharmadhikari, G; Kerr-Conte, J; Klein, T; Laue, S; Maedler, K; Pattou, F; Schumann, DM; Shah, P | 1 |
| Ando, K; Morimoto, A; Nishimura, R; Sakamoto, M; Seo, C; Tsujino, D; Utsunomiya, K | 1 |
| Caderni, G; Femia, AP; Lodovici, M; Maglieri, G; Mannucci, E; Raimondi, L | 1 |
| Assmann, G; Brenner, C; Brunner, S; David, R; Franz, WM; Gross, L; Mueller-Hoecker, J; Nathan, P; Steinbeck, G; Theiss, HD; Vallaster, M; Vogeser, M | 1 |
| Tang, Y; Wu, F; Xu, T; Zhan, M | 1 |
| Schütt, M; Steinhoff, J; Süfke, S | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Gao, H; Hu, J; Sun, R; Wang, F; Wang, L; Wang, Y; Wang, Z; Yan, S; Yu, X; Zhao, W | 1 |
| Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D | 1 |
| Chiba, S; Gotoh, K; Kakuma, T; Masaki, T; Mitsutomi, K; Shimasaki, T; Ueno, D; Yoshimatsu, H | 1 |
| Bergeson, JG; Graham, J; Louder, A; Ward, M; Worley, K | 1 |
| Alattar, M; Li, WP; Linder, G; Malek, R; Price, JD; Rother, KI; Tarbell, KV; Zimmermann, B | 1 |
| Bruce, SS; Connolly, ES; Heyer, EJ; Mergeche, JL | 1 |
| Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S | 1 |
| Han, J; Malloy, J; Meloni, A | 1 |
| Anderson, MS; Engel, SS; Hanson, ME; Musliner, T; Steinberg, H | 1 |
| Bae, JH; Cho, YM; Jung, HS; Kim, SY; Kim, YG; Oh, TJ; Park, KS | 1 |
| Ahrén, B; Alba, M; Goldstein, BJ; Guan, Y; Inzucchi, SE; Kaufman, KD; Mallick, M; O'Neill, EA; Williams-Herman, DE; Xu, L | 1 |
| Moniri, NH; Ryan, GJ; Smiley, DD | 1 |
| Chang, LT; Chen, YL; Cho, CL; Chua, S; Chung, SY; Kao, YH; Leu, S; Sheu, JJ; Sun, CK; Sung, HC; Tsai, TH; Yeh, KH; Yip, HK | 1 |
| Cander, S; Cinkilic, N; Ersoy, C; Gul, CB; Oz Gul, O; Tuncel, E; Vatan, O; Yılmaz, D | 1 |
| Farrokhi, F; Gianchandani, R; Jacobs, S; Lathkar-Pradhan, S; Newton, C; Pasquel, F; Peng, L; Reyes, D; Smiley, D; Umpierrez, GE; Wesorick, DH | 1 |
| Huang, Q; Peng, Y; Wang, Y; Zhao, L | 1 |
| Fujimoto, M; He, P; Ishibashi, R; Ishikawa, T; Kawamura, H; Kobayashi, K; Okabe, E; Onishi, S; Takemoto, M; Watanabe, K; Yamaga, M; Yokote, K | 1 |
| Cimburek, Z; Dovolilová, E; Saudek, F; Vargová, L; Vojtová, L; Zacharovová, K | 1 |
| Antonio, EL; Arruda-Junior, DF; Barreto, AL; Campos, LC; dos Santos, L; Girardi, AC; Krieger, JE; Mansur, AJ; Pereira, AC; Salles, TA; Tucci, PJ | 1 |
| Chou, MZ; Fonseca, VA; Goldstein, BJ; Golm, GT; Henry, RR; Kaufman, KD; Langdon, RB; Staels, B; Steinberg, H; Teng, R | 1 |
| Araki, E; Furukawa, N; Goto, R; Ichimori, S; Iwashita, S; Kawashima, J; Kondo, T; Maeda, T; Matsumura, T; Matsuo, T; Matsuo, Y; Motoshima, H; Nishida, K; Sekigami, T; Shimoda, S | 1 |
| Du, Q; Liang, YY; Wang, YJ; Wu, B; Yang, S; Zhao, YY | 1 |
| Harja, E; Lord, J; Skyler, JS | 1 |
| Dang, NH; Hatano, R; Morimoto, C; Ninomiya, H; Ohnuma, K; Saito, T; Suzuki, H | 1 |
| Hu, Y; Li, J; Liu, T; Liu, Y; Ma, X; Shangguan, S; Si, M; Tang, L; Wu, H; Wu, P | 1 |
| Derosa, G; Maffioli, P | 1 |
| Chen, YC; Chen, YJ; Hsu, MI; Huang, JH; Kao, YH; Lee, TI | 1 |
| Andersson, C; Mogensen, UM; Scheller, NM; Torp-Pedersen, C; Vaag, A | 1 |
| Badole, SL; Bagul, PP; Chaudhari, SM; Joshi, AC; Khose, RD; Mahamuni, SP; Raut, CG; Zanwar, AA | 1 |
| Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C | 1 |
| Nageswara Rao, R; Padiya, R; Ramakrishna, K; Saida, S; Sravan, B | 1 |
| Bain, SC; Eligar, VS | 1 |
| Chang, G; Duan, Q; Lu, K; Qin, S; Wang, Y; Ye, L; Zhang, D; Zhang, P; Zheng, A | 1 |
| Cho, JH; Kim, ES; Kim, HS; Lee, SH; Shin, JA; Son, HY; Yoon, KH | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C | 1 |
| Kawata, T; Matsubara, F; Nagai, Y; Nakamura, Y; Ohshige, T; Ohta, A; Sakai, K; Tanaka, Y; Tenjin, A; Terashima, Y; Tsukiyama, S | 1 |
| Akay, A; Dragomir, A; Erlandsson, BE | 2 |
| Bies, RR; Broxmeyer, HE; Chitnis, SD; Farag, SS; Messina-Graham, S; Strother, RM; Vélez de Mendizábal, N | 1 |
| Hardy, E; Jabbour, SA; Parikh, S; Sugg, J | 1 |
| Begum, SS; Hausenloy, DJ; Mocanu, MM; Riksen, N; Theodorou, L; Whittington, HJ; Wynne, AM; Yellon, DM | 1 |
| Chang, CL; Chang, HW; Chang, LT; Chen, HH; Chen, YL; Chen, YT; Leu, S; Sun, CK; Sung, PH; Tsai, TH; Yang, CC; Yip, HK; Zhen, YY | 1 |
| Cappuccio, F; Ceriello, A; Genovese, S; Schnell, O; Standl, E; Valensi, P | 1 |
| Arndt, E; Deacon, CF; Holst, JJ; Nauck, MA; Vardarli, I | 1 |
| Berk, A; Broedl, UC; Ferrannini, E; Hach, T; Hantel, S; Pinnetti, S; Woerle, HJ | 1 |
| Li, H; Lu, J; Zang, J | 1 |
| Fujita, H; Hayashi, H; Kikuchi, N; Komatsu, K; Komatsu, T; Murayama, H; Narita, T; Ohshiro, H; Sato, S; Taniai, H; Yamada, Y | 1 |
| Abd El Motteleb, DM; Elshazly, SM | 1 |
| Franz, WM; Hiergeist, L; Kozlik-Feldmann, R; Mechea, A; Netz, H; Theisen, D; Zaruba, MM | 1 |
| Huh, W; Jung, JA; Kaku, K; Kim, JH; Kim, JR; Ko, JW; Lee, SY | 1 |
| Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR | 1 |
| Minoura, H; Negoro, K; Shibasaki, M; Shimaya, A; Shimokawa, T; Tanaka, H; Yoshida, S | 1 |
| Aulinger, BA; Bedorf, A; de Heer, J; Göke, B; Holst, JJ; Kutscherauer, G; Schirra, J | 1 |
| Diamant, M; Heymans, MW; Mari, A; Muskiet, MH; Ouwens, DM; Pouwels, PJ; van Genugten, RE; van Raalte, DH | 1 |
| Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J | 1 |
| Sakr, HF | 1 |
| Anz, D; Bourquin, C; Endres, S; Haubner, S; Kruger, S; Rapp, M | 1 |
| Anand, S; Bhatia, T; Olaywi, M; Singhal, S | 1 |
| Gao, Y; Huang, Y; Lau, CW; Liu, J; Liu, L; Ng, CF; Tian, XY; Wong, WT; Xu, A; Xu, G; Yao, X | 1 |
| Fathy, A; Khashab, S; Shaheen, N; Soliman, AR; Soliman, MA | 1 |
| Chen, C; Engel, FB; Lingwal, N; Linn, T; Padmasekar, M; Samikannu, B | 1 |
| Bussey, MR; Emanuele, MA; Lomasney, LM; Tehrani, R | 1 |
| Hayes, MR; McGrath, LE; Mietlicki-Baase, EG; Montaubin, O; Olivos, DR; Turner, CA | 1 |
| Czock, D; Hartmann, B; Keller, F | 1 |
| Dai, D; Dai, Y; Ding, Z; Mehta, JL; Wang, X | 2 |
| Goto, C; Mizui, T; Ohta, H; Tachi, T; Teramachi, H; Toyoshima, M; Tsuchiya, T | 1 |
| Gahler, RJ; Grover, GJ; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S | 1 |
| Gallacher, DJ; Hemmeryckx, B; Roger Lijnen, H; Rong Lu, H; Swinnen, M | 1 |
| Plosker, GL | 1 |
| Cunningham, C; Dey, M; Forest, T; Frederick, C; Holder, D; Prahalada, S; Smith, A; Yao, X | 1 |
| Huang, G; Leslie, RD; Li, X; Liu, L; Long, Z; Wang, X; Xiang, Y; Yang, L; Zhao, Y; Zhou, Z | 1 |
| Baeschlin, DK; Beswick, M; Clark, DE; Duttaroy, A; Fenton, G; Ferreira, S; Flohr, S; Gerhartz, B; Gessier, F; Hassiepen, U; Namoto, K; Ostermann, N; Sedrani, R; Sirockin, F; Sutton, JM; Trappe, J | 1 |
| Hanaoka, H; Hashimoto, N; Ishikawa, K; Kanatsuka, A; Kobayashi, K; Kuribayashi, N; Onishi, S; Sakurai, K; Sato, Y; Takemoto, M; Terano, T; Uchida, D; Yokoh, H; Yokote, K | 1 |
| Åsberg, A; Hartmann, A; Jenssen, T; Strøm Halden, TA; Vik, K | 1 |
| Nistala, R; Rao, A | 1 |
| Schnell, O | 1 |
| Guan, M; He, F; Li, C; Li, J; Wang, L; Xu, W; Xue, Y; Zeng, Y; Zheng, Z | 1 |
| Abe, J; Hara, H; Kinosada, Y; Nagasawa, H; Nakamura, M; Nishibata, Y; Suzuki, Y; Umetsu, R | 1 |
| Bond, SJ; Dutka, DP; Hoole, SP; Kydd, AC; McCormick, LM; Read, PA; Ring, LS | 1 |
| Davies, MJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Round, EM | 1 |
| Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF | 1 |
| Billings, FT; Brown, NJ; Devin, JK; Nian, H; Pretorius, M; Yu, C | 2 |
| Amemiya, H; Honda, S; Hoshino, K; Iemitsu, K; Iizuka, T; Ishikawa, M; Iwasaki, T; Kanamori, A; Kaneshige, H; Kaneshiro, M; Kawata, T; Kubota, A; Machimura, H; Maeda, H; Matoba, K; Matsuba, I; Minagawa, F; Minami, N; Miyairi, Y; Miyakawa, M; Mokubo, A; Motomiya, T; Naka, Y; Nakajima, S; Obana, M; Saito, T; Sasai, N; Takai, M; Takeda, H; Takuma, T; Tanaka, K; Tanaka, Y; Terauchi, Y; Tsurui, N; Uehara, G; Umezawa, S; Waseda, M | 1 |
| Arai, K; Hirao, K; Hirao, S; Hirao, T; Kumakura, A; Maeda, H; Shirabe, S; Yamamoto, R; Yamauchi, M | 1 |
| Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
| Hirata, T; Inukai, K; Ishida, H; Katayama, S; Morimoto, J | 1 |
| Rouse, R; Stewart, S; Xu, L; Zhang, J | 1 |
| Tibaldi, JM | 1 |
| Aragonés, A; del Val, F; López, J; Luque, A; Sastre, J | 1 |
| Fuchigami, M; Goda, T; Imai, C; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Dash, S; Lewis, GF; Morgantini, C; Patterson, BW; Xiao, C | 1 |
| Ferrannini, E; Mari, A; Polidori, D | 1 |
| Coric, J; Dizdarevic-Bostandzic, A; Djelilovic-Vranic, J; Izetbegovic, S; Karamehic, J; Macic-Dzankovic, A; Panjeta, M; Velija-Asimi, Z | 1 |
| Dong, S; Jia, J; Mao, C; Qian, W; Tang, B; Wang, D; Yang, L; Ye, J; Yu, S; Yuan, G; Zhang, C; Zhou, L; Zhu, T | 1 |
| Broedl, UC; Delafont, B; Eilbracht, J; Kim, G; Roden, M; Weng, J; Woerle, HJ | 1 |
| Borders-Hemphill, V; Hampp, C; Moeny, DG; Wysowski, DK | 1 |
| Navalgund, SG; Radhakrishnanand, P; Satheeshkumar, N; Vishnuvardhan, C | 1 |
| Gao, Y; Hao, S; Sun, J; Sun, X; Tian, X; Zhang, Z | 1 |
| Hegazy, SK | 1 |
| Bound, MJ; Checklin, H; Deacon, CF; Horowitz, M; Jones, KL; Ma, J; Rayner, CK; Wu, T | 1 |
| Fukumoto, M; Hiura, Y; Hosoi, M; Ikuno, Y; Kawasaki, I; Okada, M; Tamai, A; Tanaka, N; Ueno, H; Yakusiji, Y; Yamagami, K; Yoshida, Y | 1 |
| Bahekar, R; Jadav, P; Jain, M; Joharapurkar, A; Patel, D; Sairam, KV; Shah, SR; Singh, PK | 1 |
| Johnson, JL; Kim, MK; O'Neal, KS; Pack, CC | 1 |
| Chernoff, J; Chiang, YT; Ip, W; Jin, T; Shao, W; Song, ZE | 1 |
| Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ | 1 |
| Christensen, M; Feldt-Rasmussen, B; Holst, JJ; Hornum, M; Idorn, T; Jørgensen, MB; Knop, FK | 1 |
| He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D | 1 |
| Bailey, CJ; Diamant, M; Fouqueray, P; Inzucchi, SE; Lebovitz, HE; Pirags, V; Schernthaner, G | 1 |
| Fan, Y; Han, S; He, X; Heng, D; Li, L; Liu, W; Peng, B; Wang, Z; Xu, J; Yin, J | 1 |
| Komatsu, M; Miya, K; Noma, Y; Shima, K | 1 |
| Duke, J; Li, X; Zhang, Z | 1 |
| Guerci, B; Milicevic, Z; Nauck, M; Skrivanek, Z; Umpierrez, GE; Weinstock, RS | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Bando, YK; Ishizu, T; Kodama, K; Murohara, T; Node, K; Oyama, J; Sato, Y | 1 |
| Ambrósio, AF; Fernandes, R; Gonçalves, A; Leal, E; Marques, C; Reis, F; Ribeiro, CF | 1 |
| Gudascheva, TA; Ivanova, EA; Kapitsa, IG; Ostrovskaya, RU; Ozerova, IV; Seredenin, SB; Voronina, TA | 1 |
| Garg, K; Kumar, S; Tripathi, CD | 1 |
| Namba, M | 1 |
| Agoramoorthy, G; Chakraborty, C; Hsu, MJ | 1 |
| Fernandes, R; Fontes-Ribeiro, C; Gonçalves, A; Marques, C; Mega, C; Reis, F; Rodrigues-Santos, P; Teixeira, F; Teixeira-Lemos, E | 1 |
| Nandith, A; Ramachandran, A; Shetty, AS; Snehalath, C | 1 |
| Akcali, KC; Amber, CF; Belma, T; Bozkus, Y; Can, AK; Cicek, FA; Evren, O; Ozcinar, E; Tokcaer-Keskin, Z; Turan, B; Yusuf, B; Zeynep, TK | 1 |
| Choi, YK; Jang, BK; Jung, GS; Jung, YA; Kim, HS; Kim, JG; Kim, MK; Lee, IK; Park, KG; Seo, HY | 1 |
| Beaudouin, E; Defendi, F; Drouet, C; Moneret-Vautrin, DA; Picaud, J; Ponard, D | 1 |
| Ishida, H; Osonoi, T; Osonoi, Y; Saito, M; Tamasawa, A | 1 |
| Funahashi, T; Hayashi, M; Hibuse, T; Hirata, A; Kashine, S; Kimura, T; Kishida, K; Maeda, N; Minami, T; Nakagawa, Y; Nishizawa, H; Oka, A; Shimomura, I; Takeshita, E | 1 |
| Chi, J; Gu, W; Hong, J; Ning, G; Wang, B; Wang, W; Zhang, Y | 1 |
| Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F | 1 |
| Guthrie, R; Slee, A; Traina, S | 1 |
| Chen, TY; Hsieh, CJ | 1 |
| Inden, Y; Ishii, H; Ishikawa, S; Koyasu, M; Murohara, T; Shimano, M; Takemoto, K; Uchikawa, T; Watarai, M | 1 |
| Arai, T; Lee, P; Mori, A; Oda, H; Saeki, K; Sako, T | 1 |
| Barros, JI; Cunha, GH; d'Alva, CB; Fechine, FV; Fernandes, VO; Montenegro Júnior, RM; Moraes, ME; Moraes, MO; Souza, MH; Vale, OC | 1 |
| Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M | 1 |
| Persson, U; Steen Carlsson, K | 1 |
| Katoh, N; Nakai, N | 1 |
| Fuller, CS; Gallop, R; Gudipaty, L; Rickels, MR; Rosenfeld, NK; Schutta, MH | 1 |
| Guan, M; Li, C; Li, J; Lyv, F; Wang, C; Xue, Y; Zeng, Y; Zheng, Z | 1 |
| Camacho, X; Garg, AX; Gomes, T; Hildebrand, AM; Juurlink, DN; Yao, Z | 1 |
| Gottschalk, M; Griffin, KJ; Kyllo, JH; Rabinovitch, A; Thompson, PA | 1 |
| Eurich, DT; McAlister, FA; Minhas-Sandhu, JK; Senthilselvan, A; Weir, DL | 1 |
| Hikasa, Y; Iguchi, A; Kitagawa, H; Matsuu, A; Murahata, Y; Nishii, N; Takashima, S | 1 |
| Jin, D; Sakonjo, H; Takai, S | 1 |
| Baldi, S; Casolaro, A; Cobb, J; Ferrannini, E; Frascerra, S; Gall, W; Mari, A; Muscelli, E | 1 |
| Carr, MC; Handelsman, Y; Jones-Leone, A; Leiter, LA; Scott, R; Stewart, M; Yang, F | 1 |
| Baerts, L; Behets, GJ; D'Haese, PC; De Meester, I; Glorie, L; Verhulst, A | 1 |
| Charest, A; Couture, P; Droit, A; Kelly, I; Lamarche, B; Lépine, MC; Tremblay, AJ | 1 |
| Gudasheva, TA; Ivanova, EA; Kapitsa, IG; Michunskaya, AM; Ostrovskaya, RU; Ozerova, IV; Seredenin, SB; Taraban, KV; Voronina, TA; Zolotov, NN | 1 |
| Fukuda, S; Hirata, K; Ito, H; Kihara, H; Miyoshi, T; Nakamura, K; Oe, H; Shimada, K; Takagi, T; Watanabe, K; Yoshikawa, J; Yunoki, K | 1 |
| Gou, Z; Ma, M; Wang, F; Wang, T; Zhai, SD | 1 |
| Ban, N; Kawana, H; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Saiki, A; Shirai, K; Tatsuno, I; Yamaguchi, T | 1 |
| Ahern, T; Kirby, B; Lynch, M; O'Shea, D; Tobin, AM | 1 |
| Inoue, T; Kyou, C; Morishita, K; Ogawa, T; Taguchi, Y; Umayahara, R; Yonemoto, T | 1 |
| Nie, J; Wang, F; Wang, H; Zhang, C | 1 |
| Asai, S; Kato, H; Kondo, A; Nagai, Y; Ohta, A; Sada, Y; Sasaoka, T; Tanaka, Y | 1 |
| Aaboe, K; Akram, S; Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Kourlaba, G; Maniadakis, N; Melidonis, A; Tzanetakos, C; Verras, C | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Ametov, AS; Gusenbekova, DG | 1 |
| Ando, K; Nishimura, R; Sakamoto, M; Seo, C; Tsujino, D; Utsunomiya, K | 1 |
| Baerts, L; De Keulenaer, GW; De Meester, I; Demolder, M; Hamdani, N; Hervent, AS; Linke, WA; Matheeussen, V; Paulus, WJ; Vandekerckhove, L | 1 |
| Gillespie, DG; Jackson, EK; Mi, Z; Tofovic, SP | 1 |
| Ding, Y; Dong, L; Jiang, MH; Shah, V; Shen, WB; Sun, LL; Zhang, FF; Zheng, F | 1 |
| Chang, NC; Chen, WT; Lee, TM; Lin, SZ; Yang, CC | 1 |
| Mel'nikova, EV; Robinson, MV; Trufakin, VA | 1 |
| Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G | 1 |
| Hong, D; Wu, B; Xiao, Y; Zhao, Q; Zheng, D | 1 |
| Hsieh, CJ; Shen, FC | 1 |
| Horikawa, Y; Mikada, A; Narita, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H | 1 |
| FitzGerald, RJ; Nongonierma, AB | 1 |
| Chopra, BS; Choudhary, V; Garg, R; Garg, V; Khatri, N; Peddada, N; Sagar, A | 1 |
| Chao, TF; Chen, SJ; Chen, TJ; Chiang, CE; Huang, CM; Lin, SJ; Liu, CJ; Wang, KL; Wu, CH; Yeh, CM | 1 |
| Brenner, C; Fischer, C; Franz, WM; Grabmaier, U; Gross, L; Herbach, N; Israel, L; Kränkel, N; Kühlenthal, S; Landmesser, U; Laskowski, A; Remm, F; Speer, T; Theiss, H; Wanke, R | 1 |
| Chang, HW; Chang, MW; Chen, CH; Chen, YC; Chen, YT; Chiang, HJ; Ko, SF; Leu, S; Sung, PH; Tsai, TH; Wu, YC; Yang, CC; Yip, HK; Zhen, YY | 1 |
| Thompson, AM; Trujillo, JM | 1 |
| Agdauletova, S; Daiber, A; Hausding, M; Klein, T; Kröller-Schön, S; Li, H; Mader, M; Mikhed, Y; Münzel, T; Oelze, M; Pfeffer, A; Schulz, E; Stamm, P; Steven, S; Sudowe, S; Welschof, P; Zinßius, E | 1 |
| Kabbara, WK; Ramadan, WH | 1 |
| Ain-Shoka, AA; Attia, AS; El-Sahar, AE; Safar, MM; Zaki, HF | 1 |
| Cornell, S | 1 |
| Bailey, RA; Blonde, L; Meininger, GE; Rupnow, MF; Vijapurkar, U | 1 |
| Avram, S; Borcan, F; Buiu, C; Duda-Seiman, C; Duda-Seiman, D; Milac, AL; Pacureanu, L | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Rupnow, MF; Vijapurkar, U | 1 |
| Bandichhor, R; Bhattacharya, A; Chandrashekar, ER; Dahanukar, VH; Dwivedi, N; Gudimalla, N; Gutierrez, O; Kozlowski, MC; Metil, D | 1 |
| Baek, JH; Huh, WS; Jin, SM; Jung, JA; Kaku, K; Kim, JH; Kim, JR; Kim, MJ; Ko, JW; Lee, SY | 1 |
| Abdelghany, RH; Mahmoud, AA; Youssef, MI | 1 |
| Best, C; Laciny, E; Reeds, DN; Royal, M; Struthers, H; Yarasheski, KE | 1 |
| Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M | 1 |
| Armstrong, PW; Bethel, MA; Buse, JB; Engel, SS; Garg, J; Green, JB; Holman, RR; Josse, R; Kaufman, KD; Koglin, J; Korn, S; Lachin, JM; McGuire, DK; Pencina, MJ; Peterson, ED; Standl, E; Stein, PP; Suryawanshi, S; Van de Werf, F | 1 |
| Albert, ML; Barreira da Silva, R; Fiette, L; Ingersoll, MA; Laird, ME; Yatim, N | 1 |
| Chen, DY; Chen, TH; Cherng, WJ; Chou, CC; Hsieh, IC; Hung, KC; Lin, YS; Mao, CT; Su, FC; Tsai, ML; Wang, CC; Wang, SH; Wen, MS | 1 |
| Bhamidipati, RK; Gilibili, RR; Mullangi, R; Srinivas, NR | 1 |
| Begum, R; Garcia-Ocaña, A; Li, Y; Palit, SP; Parmar, N; Patel, R; Rathwa, N | 1 |
144 review(s) available for triazoles and sitagliptin phosphate
| Article | Year |
|---|---|
MK-431 (Merck).
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Clinical Trials as Topic; Contraindications; Dipeptidyl Peptidase 4; Drug Industry; Glycoproteins; Humans; Hypoglycemic Agents; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles | 2005 |
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glycine; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Oxazoles; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Models, Animal; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2006 |
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Isoenzymes; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
Diabetes drug update: how 4 new options stack up.
Topics: Administration, Inhalation; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Exenatide; Family Practice; Female; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Islet Amyloid Polypeptide; Male; Peptides; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2007 |
Sitagliptin.
Topics: Adenosine Deaminase Inhibitors; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Prodrugs; Pyrazines; Serine Proteinase Inhibitors; Sitagliptin Phosphate; Triazoles | 2007 |
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Enzyme Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Topics: Animals; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Resistance; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Glycoproteins; Homeostasis; Humans; Hypoglycemic Agents; Islets of Langerhans; Models, Biological; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
[New concepts in the treatment of type 2 diabetes].
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycoproteins; Humans; Isoenzymes; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2007 |
Using prandial insulin to achieve glycemic control in type 2 diabetes.
Topics: Algorithms; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Postprandial Period; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
[Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
Topics: Adenosine Deaminase Inhibitors; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2007 |
Unlocking the potential of asymmetric hydrogenation at Merck.
Topics: Drug Industry; Hydrogenation; Pyrazines; Sitagliptin Phosphate; Small Molecule Libraries; Stereoisomerism; Triazoles | 2007 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
[Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Incretins; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Molecular Structure; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2008 |
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting | 2008 |
Managed care perspective on three new agents for type 2 diabetes.
Topics: Amyloid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Managed Care Programs; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms | 2008 |
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
[New drugs; exenatide and sitagliptin].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2008 |
New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Peptide Fragments; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes.
Topics: Adult; Aged; Blood Pressure; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lipids; Male; Pregnancy; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Drugs for type 2 diabetes.
Topics: alpha-Galactosidase; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Piperidines; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
What's new in clinical pharmacology and therapeutics.
Topics: Abatacept; Acetanilides; Amides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiparkinson Agents; Antirheumatic Agents; Antiviral Agents; Apomorphine; Benzazepines; Cardiovascular Agents; Fumarates; Hepatitis B; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Hypoglycemic Agents; Immunoconjugates; Multiple Sclerosis; Natalizumab; Nucleosides; Papillomavirus Vaccines; Pharmacology, Clinical; Piperazines; Pyrazines; Pyrimidinones; Quinoxalines; Ranolazine; Sitagliptin Phosphate; Smoking Cessation; Telbivudine; Thymidine; Triazoles; Varenicline; Viral Vaccines | 2008 |
From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Topics: Adamantane; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Nitriles; Protein Conformation; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Structure-Activity Relationship; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
New treatments for type 2 diabetes--the DPP4 inhibitors.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin | 2007 |
DPP4 inhibitors: a new approach in diabetes treatment.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes.
Topics: Animals; Biomarkers; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
DPP4 inhibitors for diabetes--what next?
Topics: Adamantane; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Hypoxia; Neoplasms; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Natural products as inspiration for the development of asymmetric catalysis.
Topics: Biological Products; Carbazoles; Catalysis; Diterpenes; Indans; Indole Alkaloids; Indolizines; Lactams; Pyrazines; Sitagliptin Phosphate; Spiro Compounds; Triazoles | 2008 |
Janumet: a combination product suitable for use in patients with Type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles | 2008 |
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
[Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Incretin-based therapies in type 2 diabetes: a review of clinical results.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
The role of incretins in glucose homeostasis and diabetes treatment.
Topics: Animals; Diabetes Mellitus; Exenatide; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2008 |
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil | 2009 |
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Impact of sitagliptin on markers of beta-cell function: a meta-analysis.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Homeostasis; Humans; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Placebos; Proinsulin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2009 |
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
[The value of incretin based therapies].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
[Incretin related agents for treatment of diabetes mellitus].
Topics: Adamantane; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.
Topics: Bayes Theorem; Confidence Intervals; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2009 |
Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.
Topics: Diabetes Mellitus, Type 2; Dimerization; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycosylation; Humans; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2009 |
Defining the importance of daily glycemic control and implications for type 2 diabetes management.
Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles | 2009 |
Inventing and understanding catalytic, enantioselective reactions.
Topics: Aldehyde Reductase; Amination; Catalysis; Chemistry, Pharmaceutical; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Hydrogenation; Hypoglycemic Agents; Models, Chemical; Molecular Structure; Pyrazines; Sitagliptin Phosphate; Spiro Compounds; Stereoisomerism; Triazoles | 2009 |
DPP-4 inhibitors in clinical practice.
Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Intracellular Signaling Peptides and Proteins; Peptides; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.
Topics: Adamantane; Amino Acid Sequence; Chemistry, Pharmaceutical; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Molecular Sequence Data; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2010 |
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2010 |
Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Incretin-based therapies: review of current clinical trial data.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2010 |
[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Risk Factors; Satiety Response; Sitagliptin Phosphate; Triazoles; Weight Loss | 2010 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Pancreatitis; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Triazoles | 2010 |
[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
Topics: Administration, Oral; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2010 |
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss | 2010 |
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2010 |
Incretin physiology and its role in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin | 2010 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Sitagliptin and metformin--novel combination therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.
Topics: Algorithms; Chronic Disease; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Humans; Hypoglycemic Agents; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
The importance of green chemistry in process research and development.
Topics: Biocatalysis; Fluorobenzenes; gamma-Aminobutyric Acid; Green Chemistry Technology; Lipase; Pharmaceutical Preparations; Pregabalin; Pyrazines; Pyrimidines; Rosuvastatin Calcium; Sitagliptin Phosphate; Solvents; Sulfonamides; Transaminases; Triazoles | 2012 |
Sitagliptin: a review.
Topics: Administration, Oral; Algorithms; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
Topics: Adult; Blood Glucose; Capsules; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Lactic Acid; Peptides; Pioglitazone; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2011 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Why do metabolites circulate?
Topics: Antifungal Agents; Dipeptidyl-Peptidase IV Inhibitors; Fluconazole; Glucuronides; Humans; Liver; Metabolome; Pharmaceutical Preparations; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.
Topics: Aged, 80 and over; Biguanides; Blood Glucose; Depressive Disorder; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Overdose; Female; Glucose; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Suicide, Attempted; Sulfonylurea Compounds; Triazoles | 2012 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Medication Adherence; Patient Satisfaction; Peptides; Pyrazines; Self Care; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Male; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2012 |
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Topics: Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Pyrroles; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Immunotherapies in diabetes mellitus type 1.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Azathioprine; Basiliximab; Chaperonin 60; Cyclosporine; Daclizumab; Diabetes Mellitus, Type 1; Diet; Etanercept; Exenatide; Fatty Acids, Unsaturated; Glutamate Decarboxylase; Humans; Hypoglycemic Agents; Immunoconjugates; Immunoglobulin G; Immunosuppressive Agents; Insulin; Interferon-alpha; Interleukin 1 Receptor Antagonist Protein; Islets of Langerhans Transplantation; Niacinamide; Peptide Fragments; Peptides; Primary Prevention; Pyrazines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Rituximab; Secondary Prevention; Sitagliptin Phosphate; Tertiary Prevention; Triazoles; Venoms; Vitamin D; Vitamins | 2012 |
[Liraglutide: new results in the treatment of type 2 diabetes mellitus].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2012 |
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Young Adult | 2013 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Liraglutide in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Molecular Structure; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2013 |
Sitagliptin in the treatment of type 2 diabetes: a meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Topics: Adamantane; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular System; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Lipids; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.
Topics: Biomarkers; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Lipids; Pyrazines; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2013 |
Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis.
Topics: Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Pyrazines; Renal Insufficiency, Chronic; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2013 |
Type 1 diabetes and cardiovascular disease.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Exenatide; Exercise Therapy; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Insulin; Oxidative Stress; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Metformin; Outcome Assessment, Health Care; Pioglitazone; Proinsulin; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.
Topics: Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Liver; Non-alcoholic Fatty Liver Disease; Peptides; Pyrazines; Sitagliptin Phosphate; Transaminases; Treatment Outcome; Triazoles; Venoms | 2013 |
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Is there a role for the incretin system in blood pressure regulation?
Topics: Animals; Blood Pressure; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypertension; Incretins; Oxidative Stress; Peptides; Pyrazines; Renin-Angiotensin System; Sitagliptin Phosphate; T-Lymphocytes, Regulatory; Triazoles; Venoms | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult | 2014 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Clinical review of sitagliptin: a DPP-4 inhibitor.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Incretins; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
[Programs for continuing medical education: a session; 7. Recent trends in treatment of diabetes mellitus].
Topics: Acarbose; Biguanides; Blood Glucose Self-Monitoring; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Routes; Drug Design; Drug Therapy, Combination; Education, Medical, Continuing; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Maculopapular-type drug eruption caused by sitagliptin phosphate hydrate: a case report and mini-review of the published work.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Eruptions; Female; Humans; Hypersensitivity, Delayed; Hypoglycemic Agents; Immunologic Tests; Lymphocyte Activation; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Skin; Triazoles; Withholding Treatment | 2014 |
Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Lipids; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Protective factors in diabetic retinopathy: focus on blood-retinal barrier.
Topics: Animals; Blood-Retinal Barrier; Diabetic Retinopathy; Erythropoietin; Fenofibrate; Humans; Insulin-Like Growth Factor Binding Protein 3; Macular Edema; Protective Factors; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Endothelial Growth Factor A | 2014 |
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2014 |
Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials.
Topics: Diabetes Mellitus, Type 2; Diarrhea; Humans; Hypoglycemic Agents; Odds Ratio; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Sitagliptin Phosphate; Triazoles | 2014 |
Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors.
Topics: Animals; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Kidney; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Reperfusion Injury; Sitagliptin Phosphate; Triazoles; Up-Regulation | 2015 |
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2015 |
Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemia; Polypharmacy; Pyrazines; Risk Factors; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain | 2015 |
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2015 |
Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
Topics: Blood Pressure; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles | 2015 |
221 trial(s) available for triazoles and sitagliptin phosphate
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Topics: Administration, Oral; Adolescent; Adult; Analysis of Variance; Area Under Curve; Blood Glucose; C-Peptide; Common Cold; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Eye Diseases; Fasting; Glucagon-Like Peptide 1; Half-Life; Headache; Humans; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2005 |
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Topics: Administration, Oral; Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Glucagon-Like Peptide 1; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Male; Middle Aged; Pyrazines; Reference Values; Sitagliptin Phosphate; Triazoles | 2006 |
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Administration, Oral; Blood Glucose; Body Weight; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycoproteins; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Topics: Adenosine Deaminase Inhibitors; Adult; Area Under Curve; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2006 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Placebos; Proinsulin; Protease Inhibitors; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Triazoles | 2006 |
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2006 |
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Carbon Radioisotopes; Cyclization; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Feces; Glucuronides; Glycoproteins; Humans; Hydroxylation; Hypoglycemic Agents; In Vitro Techniques; Kidney; Male; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Pyrazines; Recombinant Proteins; Reference Values; Sitagliptin Phosphate; Sulfuric Acid Esters; Triazoles | 2007 |
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
Topics: Adenosine Deaminase Inhibitors; Adult; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glycoproteins; Humans; Hypoglycemic Agents; Male; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2007 |
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
Topics: Adenosine Deaminase Inhibitors; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cyclosporine; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glycoproteins; Humans; Hypoglycemic Agents; Kidney; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Patient Selection; Placebos; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Triazoles | 2007 |
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Chromatography, High Pressure Liquid; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Half-Life; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Tablets; Tandem Mass Spectrometry; Triazoles | 2007 |
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Half-Life; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Pyrazines; Sitagliptin Phosphate; Tablets; Triazoles | 2007 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.
Topics: Adult; Age of Onset; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Placebos; Pyrazines; Safety; Sitagliptin Phosphate; Triazoles | 2008 |
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Triglycerides | 2008 |
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.
Topics: Adult; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
Topics: Aged; Blood Glucose; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Placebos; Pyrazines; Renal Insufficiency, Chronic; Severity of Illness Index; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Stomach; Triazoles; Venoms | 2008 |
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
Topics: Adult; Aged; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; India; Korea; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Effect of sitagliptin on the pharmacokinetics of simvastatin.
Topics: Adult; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pyrazines; Simvastatin; Sitagliptin Phosphate; Time Factors; Triazoles | 2009 |
Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Topics: Administration, Oral; Aged; Area Under Curve; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Half-Life; Hepatic Insufficiency; Humans; Liver Function Tests; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2009 |
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Middle Aged; Patient Selection; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult | 2009 |
Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.
Topics: Adolescent; Adult; Aza Compounds; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Humans; Male; Middle Aged; Models, Biological; Moxifloxacin; Pyrazines; Quinolines; Sensitivity and Specificity; Sitagliptin Phosphate; Time Factors; Triazoles; Young Adult | 2009 |
Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Humans; Hypoglycemic Agents; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2009 |
Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
Topics: Adolescent; Adult; Anticoagulants; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Interactions; Female; Humans; International Normalized Ratio; Male; Middle Aged; Prothrombin Time; Pyrazines; Sitagliptin Phosphate; Triazoles; Warfarin | 2009 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Resistin; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Tumor Necrosis Factor-alpha | 2010 |
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.
Topics: Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucose Intolerance; Humans; Incretins; Male; Middle Aged; Placebos; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Myocardial Infarction; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2010 |
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Preprandial single oral dose of sitagliptin does not affect circulating ghrelin and gastrin levels in normal subjects.
Topics: Administration, Oral; Adult; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastrins; Ghrelin; Humans; Hypoglycemic Agents; Insulin; Male; Postprandial Period; Pyrazines; Radioimmunoassay; Sitagliptin Phosphate; Tablets; Time Factors; Triazoles | 2010 |
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2010 |
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
Topics: Administration, Oral; Adult; Aged; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelial Cells; Enzyme Activation; Female; Hematopoietic Stem Cells; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pilot Projects; Pyrazines; Receptors, CXCR4; Sitagliptin Phosphate; Triazoles | 2010 |
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Peptide YY; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes].
Topics: Adult; Aged; Aged, 80 and over; Belgium; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Satisfaction; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Treatment Outcome; Triazoles; Young Adult | 2010 |
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2010 |
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Food; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Kinetics; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid A; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Topics: Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enalapril; Female; Heart Rate; Hemodynamics; Humans; Insulin; Male; Metabolic Syndrome; Middle Aged; Peptidyl-Dipeptidase A; Prospective Studies; Pyrazines; Renal Circulation; Sitagliptin Phosphate; Sodium; Triazoles | 2010 |
Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose.
Topics: Aged; Blood Glucose; Body Mass Index; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Hyperglycemia; Incretins; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Liver; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2010 |
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pilot Projects; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
Topics: Administration, Oral; Adult; Blood Glucose; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Tablets; Therapeutic Equivalency; Treatment Outcome; Triazoles; United States; Young Adult | 2010 |
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers.
Topics: Capsaicin; Carbonated Beverages; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Eruptions; Edema; Erythema; Humans; Injections, Intradermal; Male; Pain; Pyrazines; Sitagliptin Phosphate; Skin; Substance P; Triazoles; Vasodilation | 2011 |
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2011 |
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2011 |
Sitagliptin reduces albuminuria in patients with type 2 diabetes.
Topics: Albuminuria; Anti-Inflammatory Agents; Blood Pressure; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects.
Topics: Adult; Contraceptives, Oral, Combined; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Ethinyl Estradiol; Female; Humans; Norethindrone; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult | 2011 |
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2011 |
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Female; Health Status; Humans; Hypoglycemic Agents; Male; Mental Health; Middle Aged; Patient Satisfaction; Peptides; Pioglitazone; Pyrazines; Quality of Life; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Topics: Administration, Oral; Adult; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Research Design; Sitagliptin Phosphate; Statistics as Topic; Triazoles; Young Adult | 2011 |
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypertension; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2011 |
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2011 |
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2011 |
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Male; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles | 2011 |
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
[Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].
Topics: Austria; Diabetes Mellitus, Type 2; Drug Tolerance; Female; Humans; Male; Metformin; Middle Aged; Prevalence; Primary Health Care; Prospective Studies; Pyrazines; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Weight Gain | 2011 |
Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
Topics: Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2011 |
The metabolic syndrome influences the response to incretin-based therapies.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2011 |
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients.
Topics: Administration, Oral; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glutamine; Humans; Hyperglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms; Young Adult | 2011 |
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
Topics: Age Factors; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Insulin; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.
Topics: Aged; Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Female; Ghrelin; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Turkey | 2011 |
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Food-Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.
Topics: Adult; Aged; Asia; Asian People; Biomarkers; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles; United States | 2011 |
The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Substitution; Fasting; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Islam; Male; Middle Aged; Middle East; Pyrazines; Residence Characteristics; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Young Adult | 2011 |
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2012 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.
Topics: Adult; Biological Availability; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Gemfibrozil; Half-Life; Humans; Hypolipidemic Agents; India; Male; Metabolic Clearance Rate; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult | 2012 |
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.
Topics: Administration, Oral; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Male; Middle Aged; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti
Topics: Adolescent; Adult; Aged; Argentina; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Germany; Glycated Hemoglobin; Greece; Humans; Hypoglycemia; Hypoglycemic Agents; India; Male; Metformin; Mexico; Middle Aged; Peptides; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2012 |
Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Topics: Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2012 |
Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Waist Circumference | 2012 |
The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Stiffness; Young Adult | 2012 |
Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2012 |
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections | 2012 |
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Triazoles | 2012 |
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Antifungal Agents; Blood Glucose; Canagliflozin; Candida; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Vagina | 2012 |
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
Topics: Abdominal Pain; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Diarrhea; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Fasting; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Inflammation; Interleukin-18; Interleukin-6; Male; Metformin; Middle Aged; Nitriles; Oxidative Stress; Postprandial Period; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2012 |
The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.
Topics: Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Intestinal Absorption; Male; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult | 2012 |
Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemia; Hypoglycemic Agents; India; Islam; Malaysia; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Young Adult | 2012 |
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Sitagliptin exerts an antinflammatory action.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blotting, Western; C-Reactive Protein; Cell Separation; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; I-kappa B Kinase; Interleukin-6; Male; MAP Kinase Kinase 4; Middle Aged; Monocytes; Prospective Studies; Pyrazines; Receptors, CCR2; Sitagliptin Phosphate; Toll-Like Receptor 2; Toll-Like Receptor 4; Triazoles; Tumor Necrosis Factor-alpha | 2012 |
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2012 |
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Triazoles | 2012 |
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult | 2012 |
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Metformin; Nausea; Patient Satisfaction; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Weight Loss | 2013 |
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; C-Peptide; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Japan; Male; Middle Aged; Monitoring, Ambulatory; Natriuretic Peptide, Brain; Nitriles; Pilot Projects; Plasminogen Activator Inhibitor 1; Postprandial Period; Predictive Value of Tests; Pyrazines; Pyrrolidines; Serum Albumin; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2012 |
[Efficacy of tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China].
Topics: Adult; Aged; Aged, 80 and over; China; Chromium; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Picolinic Acids; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients.
Topics: Aged; Asian People; Body Mass Index; Body Weight; C-Peptide; Demography; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Pyrazines; ROC Curve; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Italy; Lipids; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
Topics: Area Under Curve; Benzhydryl Compounds; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles | 2012 |
A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Topics: Blood Glucose; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Inflammation; Interleukin-10; Interleukin-6; Leukocytes, Mononuclear; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrazines; Regression Analysis; Serum Amyloid A Protein; Sitagliptin Phosphate; Triazoles; Tumor Necrosis Factor-alpha | 2013 |
The effects of simvastatin on the pharmacokinectics of sitagliptin.
Topics: Adult; Area Under Curve; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrazines; Simvastatin; Sitagliptin Phosphate; Triazoles; Young Adult | 2012 |
The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.
Topics: Adiponectin; Aged; Aged, 80 and over; Atherosclerosis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Nitroglycerin; Prospective Studies; Pyrazines; Regression Analysis; Sitagliptin Phosphate; Triazoles; Vasodilation; Vasodilator Agents | 2012 |
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Pyrazines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles | 2013 |
Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study.
Topics: Adolescent; Adult; Aged; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; HIV Infections; HIV Seropositivity; Humans; Male; Middle Aged; Pilot Projects; Pyrazines; RNA, Viral; Sitagliptin Phosphate; Triazoles | 2013 |
In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies.
Topics: Adult; Cord Blood Stem Cell Transplantation; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Fetal Blood; Hematologic Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Transplantation Conditioning; Triazoles; Young Adult | 2013 |
Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics.
Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Research Design; Sitagliptin Phosphate; Triazoles | 2012 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrazines; Pyrimidines; Republic of Korea; Risk Reduction Behavior; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.
Topics: Acute Coronary Syndrome; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Pyrazines; Renal Dialysis; Sitagliptin Phosphate; Triazoles | 2013 |
Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Radioimmunoassay; Sitagliptin Phosphate; Triazoles; Xylose | 2013 |
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
Topics: Adamantane; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Inflammation; Nitriles; Oxidative Stress; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Tyrosine; Vildagliptin | 2013 |
Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.
Topics: Adult; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Cohort Studies; Colorado; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Genetic Association Studies; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Clearance Rate; Middle Aged; Polymorphism, Single Nucleotide; Pyrazines; Pyrroles; Sitagliptin Phosphate; Triazoles; Young Adult | 2013 |
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Topics: Animals; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Glucagon-Like Peptide 1; Glycosides; Humans; Hypoglycemic Agents; Mice; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Triazoles | 2013 |
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2013 |
Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
Topics: Adult; Diabetes Mellitus, Type 1; Exenatide; Female; Humans; Insulin; Male; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Young Adult | 2013 |
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol; Japan; Linear Models; Male; Middle Aged; Piperidines; Prospective Studies; Pyrazines; Regional Blood Flow; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Uracil; Vasodilation | 2013 |
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.
Topics: Administration, Oral; Argentina; Blood Glucose; Body Weight; Canada; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; India; Insulin, Long-Acting; Male; Mexico; Middle Aged; Pyrazines; Sitagliptin Phosphate; South Africa; Treatment Outcome; Triazoles; Turkey; United States | 2013 |
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Young Adult | 2013 |
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study.
Topics: Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Glucagon-Like Peptide 1; Humans; Immunomodulation; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; T-Lymphocyte Subsets; Time Factors; Transforming Growth Factor beta; Triazoles; Up-Regulation | 2013 |
Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Middle Aged; Pioglitazone; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inpatients; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2014 |
Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
Topics: Aged; Asian People; Blood Glucose; Blood Glucose Self-Monitoring; Body Mass Index; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2013 |
A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Topics: Adult; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxidative Stress; Patient Compliance; Prospective Studies; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2013 |
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss | 2014 |
Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes.
Topics: Aged; Asian People; Blood Glucose; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Inositol; Insulin; Isoindoles; Male; Middle Aged; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles | 2013 |
Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycemic Index; Humans; Hypoglycemic Agents; Inflammation Mediators; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss | 2014 |
Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gene Expression Regulation; Glucose; Humans; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Chemokine CXCL12; Cross-Over Studies; Cyclic AMP; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Piperidines; Pyrazines; Receptor, Angiotensin, Type 1; Sitagliptin Phosphate; Triazoles; Up-Regulation; Uracil | 2014 |
Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Confidence Intervals; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Isoindoles; Male; Middle Aged; Postprandial Period; Prospective Studies; Pyrazines; Reference Values; Severity of Illness Index; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Gastric Emptying; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles | 2014 |
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Glucocorticoids; Glucose Intolerance; Humans; Insulin Resistance; Islets of Langerhans; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Prednisolone; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Kidney Transplantation; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain; Weight Loss | 2013 |
Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i
Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastrointestinal Agents; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postprandial Period; Prospective Studies; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography, Doppler; Echocardiography, Stress; Electrocardiography; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Heart Ventricles; Humans; Male; Myocardial Ischemia; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Stroke Volume; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left | 2014 |
Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles | 2014 |
Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Bradykinin; Cross-Over Studies; Dipeptidyl Peptidase 4; Double-Blind Method; Enalaprilat; Enzyme Inhibitors; Female; Heart Rate; Humans; Male; Middle Aged; Neurotransmitter Agents; Norepinephrine; Peptidyl-Dipeptidase A; Pyrazines; Sitagliptin Phosphate; Substance P; Sympathetic Nervous System; Triazoles; Vascular Resistance | 2014 |
Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Adult; Aged; Asian People; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Interleukin-8; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vascular Cell Adhesion Molecule-1 | 2014 |
Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans.
Topics: Adult; Apolipoproteins B; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Intestinal Mucosa; Intestines; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Triglycerides | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles | 2014 |
The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides | 2013 |
Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Infusions, Subcutaneous; Insulin; Insulin Infusion Systems; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Analysis of Variance; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles | 2013 |
Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Lumbar Vertebrae; Metformin; Middle Aged; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Postmenopause; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Energy Intake; Gastric Inhibitory Polypeptide; Gastrointestinal Motility; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles | 2014 |
Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease.
Topics: Adult; Blood Glucose; Denmark; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Insulin; Kidney Failure, Chronic; Male; Middle Aged; Peptide Fragments; Proteolysis; Pyrazines; Renal Dialysis; Sitagliptin Phosphate; Triazoles | 2014 |
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazines; Triazoles | 2014 |
Glycated albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles | 2014 |
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study.
Topics: Adult; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Prospective Studies; Pyrazines; Research Design; Sitagliptin Phosphate; Triazoles | 2014 |
Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
Topics: Acarbose; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Female; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Isoindoles; Male; Middle Aged; Prospective Studies; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles | 2014 |
A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study.
Topics: Adiponectin; Aged; Asian People; Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Follow-Up Studies; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2015 |
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2014 |
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss | 2014 |
Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Carotid Arteries; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Tunica Intima; Ultrasonography | 2014 |
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.
Topics: Activation, Metabolic; Adult; Alanine Transaminase; Area Under Curve; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Evoked Potentials, Somatosensory; Fasting; Female; Food, Formulated; gamma-Glutamyltransferase; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Statistics, Nonparametric; Triazoles; Triglycerides | 2014 |
Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin.
Topics: Adult; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Peptides; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Venoms; Young Adult | 2014 |
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lansoprazole; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; United States | 2014 |
Effects of sitagliptin on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats.
Topics: Administration, Oral; Animal Feed; Animals; Cats; Esophagostomy; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Incretins; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cell Adhesion Molecules; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; E-Selectin; Endothelium, Vascular; Female; Glucagon-Like Peptide 1; Humans; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Phospholipases A2, Secretory; Pyrazines; Sitagliptin Phosphate; Solubility; Triazoles | 2014 |
The amino acid response to a mixed meal in patients with type 2 diabetes: effect of sitagliptin treatment.
Topics: Adult; Aged; Amino Acids; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Humans; Hydroxybutyrates; Insulin; Insulin Resistance; Male; Meals; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Receptors, Glucagon; Renal Insufficiency; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes.
Topics: Apolipoprotein B-48; Apolipoproteins; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides | 2014 |
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycoside Hydrolase Inhibitors; Humans; Inositol; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult | 2014 |
Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Malondialdehyde; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
Topics: Adult; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Forearm; Glucagon-Like Peptide 1; Healthy Volunteers; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Pyrazines; Regional Blood Flow; Sitagliptin Phosphate; Triazoles; Vasodilation | 2014 |
Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Japan; Kidney; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Up-Regulation | 2015 |
[Effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus].
Topics: Blood Glucose; Body Mass Index; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Intra-Abdominal Fat; Lipid Metabolism; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Isoindoles; Middle Aged; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
The durability of sitagliptin in elderly patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Body Mass Index; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Diagnostic Techniques, Ophthalmological; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Urinalysis | 2014 |
Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incretins; Intra-Abdominal Fat; Japan; Male; Middle Aged; Overweight; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
Topics: Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2014 |
More effective DPP4 inhibitors as antidiabetics based on sitagliptin applied QSAR and clinical methods.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Female; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Male; Middle Aged; Models, Molecular; Pyrazines; Quantitative Structure-Activity Relationship; Romania; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Isoindoles; Male; Middle Aged; Postprandial Period; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults With Impaired Glucose Tolerance.
Topics: Adipokines; Adult; Chemokines; Endothelial Progenitor Cells; Female; Glucose Intolerance; HIV Infections; HIV-1; Humans; Hypoglycemic Agents; Inflammation; Lymphocyte Activation; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Topics: 1-Deoxynojirimycin; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sorbitol; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2015 |
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Heart Diseases; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
376 other study(ies) available for triazoles and sitagliptin phosphate
| Article | Year |
|---|---|
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Binding Sites; Biochemistry; Blood Glucose; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Models, Molecular; Peptide Fragments; Protein Conformation; Protein Precursors; Pyrazines; Rats; Sitagliptin Phosphate; Structure-Activity Relationship; Triazoles | 2005 |
American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Nitriles; Peptide Fragments; Protease Inhibitors; Protein Precursors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin; Xanthines | 2005 |
Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Freezing; Humans; Hypoglycemic Agents; Online Systems; Pyrazines; Quality Control; Reproducibility of Results; Sitagliptin Phosphate; Solvents; Tandem Mass Spectrometry; Triazoles | 2006 |
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Disease Models, Animal; Dyslipidemias; Glipizide; Hypoglycemic Agents; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred ICR; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2006 |
American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA.
Topics: Adamantane; Clinical Trials as Topic; Glucagon-Like Peptide 1; Humans; Liraglutide; Nitriles; Peripheral Vascular Diseases; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
[DPP-4 inhibition raises incretin levels].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon-Like Peptide 1; Humans; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs.
Topics: Animals; Area Under Curve; Cathepsin C; Enzyme Inhibitors; Growth Hormone-Releasing Hormone; Insulin-Like Growth Factor I; Male; Pyrazines; Sitagliptin Phosphate; Swine; Triazoles | 2006 |
Oral agents for type 2 diabetes reduce HbA1c, are weight neutral.
Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Animals; Azepines; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Protease Inhibitors; Protein Conformation; Pyrazines; Rats; Rats, Inbred Strains; Sitagliptin Phosphate; Triazoles | 2007 |
The development of a stable, coated pellet formulation of a water-sensitive drug, a case study: development of a stable core formulation.
Topics: Chemistry, Pharmaceutical; Coated Materials, Biocompatible; Drug Delivery Systems; Drug Stability; Glycerides; Hydrolysis; Microspheres; Pyrazines; Sitagliptin Phosphate; Triazoles; Water | 2006 |
First-in-class diabetes drug approved.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Sitagliptin (Januvia) for type 2 diabetes.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Characterization of two cyclic metabolites of sitagliptin.
Topics: Animals; Biotransformation; Cyclization; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Enzyme Inhibitors; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Molecular Structure; Oxidation-Reduction; Pyrazines; Sitagliptin Phosphate; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism; Tandem Mass Spectrometry; Triazoles | 2007 |
Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Bile; Biological Availability; Biotransformation; Cyclization; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Enzyme Inhibitors; Feces; Glucuronides; Glycoproteins; Haplorhini; Humans; Hydroxylation; Hypoglycemic Agents; In Vitro Techniques; Kidney; Male; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Protein Binding; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Species Specificity; Sulfuric Acid Esters; Triazoles | 2007 |
Finding new treatments for diabetes--how many, how fast... how good?
Topics: Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Glucagon-Like Peptide 1; Glycoproteins; History, 20th Century; History, 21st Century; Humans; Hypoglycemic Agents; Peptide Fragments; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration | 2007 |
Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.
Topics: Adenosine Deaminase Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; CHO Cells; Cricetinae; Cricetulus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glycoproteins; Humans; Male; Membrane Transport Proteins; Mice; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Sitagliptin.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2007 |
Sitagliptin: a viewpoint by Mark S. Kipnes.
Topics: Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Sitagliptin: a viewpoint by Itamar Raz.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.
Topics: Adenosine Deaminase Inhibitors; Administration, Oral; Binding Sites; Crystallography, X-Ray; Cyclohexylamines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Glycoproteins; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Models, Chemical; Models, Molecular; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate).
Topics: Amides; Animals; Dipeptidyl-Peptidase IV Inhibitors; Piperazines; Protease Inhibitors; Pyrazines; Rats; Sitagliptin Phosphate; Structure-Activity Relationship; Triazoles | 2007 |
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Triazoles | 2007 |
New treatments for diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin | 2007 |
New treatments for diabetes.
Topics: Adenosine Deaminase Inhibitors; Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2007 |
New treatments for diabetes.
Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration | 2007 |
New treatments for diabetes.
Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Glycoproteins; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration | 2007 |
Sitagliptin/metformin (Janumet) for type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Janumet.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
[New class of oral antidiabetic drugs. Effective in combination with metformin].
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Treatment of type 2 diabetes mellitus and the incretin system.
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; United States; Venoms | 2007 |
New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.
Topics: Diabetes Mellitus; Diabetic Angiopathies; Exenatide; Heart Diseases; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Type 2 diabetes drug boom: is newer better?
Topics: Amyloid; Diabetes Mellitus; Exenatide; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Type 2 diabetes: the end of clinical inertia.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Nebulizers and Vaporizers; Peptides; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2007 |
Management of comorbid diabetes and cancer.
Topics: Ambulatory Care; Amyloid; Comorbidity; Diabetes Mellitus; Exenatide; Humans; Hypoglycemic Agents; Inpatients; Insulin; Islet Amyloid Polypeptide; Neoplasms; Peptides; Practice Guidelines as Topic; Pyrazines; Quality of Life; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2007 |
How lithium treatment generates neutrophilia by enhancing phosphorylation of GSK-3, increasing HIF-1 levels and how this path is important during engraftment.
Topics: Animals; Chemokine CXCL12; Dipeptidyl Peptidase 4; Glycogen Synthase Kinase 3; Hematopoietic Stem Cells; Humans; Hypoxia-Inducible Factor 1; Lithium Compounds; Neutrophils; Phosphorylation; Pyrazines; Receptors, CXCR4; Sitagliptin Phosphate; Triazoles | 2008 |
Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction.
Topics: Chromatography, High Pressure Liquid; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Reproducibility of Results; Sitagliptin Phosphate; Spectrometry, Mass, Electrospray Ionization; Triazoles | 2008 |
Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Determination of sitagliptin in human urine and hemodialysate using turbulent flow online extraction and tandem mass spectrometry.
Topics: Calibration; Chromatography, Liquid; Drug Stability; Hemodialysis Solutions; Humans; Pyrazines; Sensitivity and Specificity; Sitagliptin Phosphate; Tandem Mass Spectrometry; Triazoles | 2008 |
Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Topics: Animals; Blood Glucose; Cell Culture Techniques; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Graft Survival; Hypoglycemic Agents; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].
Topics: Belgium; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Models, Economic; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension.
Topics: Angiotensin II; Animals; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Hypertension, Renal; Kidney; Male; Neuropeptide Y; Peptide Fragments; Pyrazines; Rats; Rats, Inbred SHR; Renal Circulation; Sitagliptin Phosphate; Sympathetic Nervous System; Triazoles; Vasoconstrictor Agents | 2008 |
New drug update: 2007.
Topics: Aged; Amides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antiparkinson Agents; Antipsychotic Agents; Drug Approval; Fumarates; Humans; Hypoglycemic Agents; Isoxazoles; Macular Degeneration; Paliperidone Palmitate; Pyrazines; Pyrimidines; Ranibizumab; Sitagliptin Phosphate; Tetrahydronaphthalenes; Thiophenes; Triazoles; United States | 2008 |
[Sitagliptine (Januvia)].
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Incretins; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Pyrazines; Sitagliptin Phosphate; Sympathetic Nervous System; Treatment Outcome; Triazoles | 2008 |
Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure.
Topics: Cell Division; Chemokine CXCL12; Dipeptidyl-Peptidase IV Inhibitors; Female; Graft Rejection; Hematopoietic Stem Cells; Humans; Hydrolysis; Leukemia, Myeloid, Acute; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Three new drugs for type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2008 |
[New drugs; exenatide and sitagliptin].
Topics: Exenatide; Glucagon-Like Peptide 1; Humans; Insulin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2008 |
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
Topics: Animals; Blood Glucose; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucose Clamp Technique; Glucose Tolerance Test; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred C57BL; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors.
Topics: Binding Sites; Chemistry, Pharmaceutical; Crystallography, X-Ray; Cytochrome P-450 CYP3A; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Inhibitory Concentration 50; Models, Chemical; Molecular Structure; Piperazine; Piperazines; Pyrazines; Sitagliptin Phosphate; Structure-Activity Relationship; Triazoles | 2008 |
[Sitagliptin].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Patient Selection; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles | 2008 |
[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 1; Exenatide; Humans; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Nitriles; Peptides; Pyrazines; Pyrrolidines; Regeneration; Sitagliptin Phosphate; Stem Cell Transplantation; Transplantation, Heterologous; Triazoles; Venoms; Vildagliptin | 2008 |
Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.
Topics: Acute Kidney Injury; Aged; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrazines; Rhabdomyolysis; Simvastatin; Sitagliptin Phosphate; Triazoles | 2008 |
What can we learn from drug marketing efficiency?
Topics: Adverse Drug Reaction Reporting Systems; Drug Approval; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Marketing; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles | 2008 |
Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.
Topics: Animals; Diabetes Mellitus, Type 1; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Graft Rejection; Graft Survival; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred NOD; Pyrazines; Sitagliptin Phosphate; T-Lymphocytes; Transplantation, Isogeneic; Triazoles | 2009 |
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Treatment Outcome; Triazoles; Vildagliptin | 2009 |
Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues.
Topics: Animals; Cattle; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Epididymis; Genitalia, Male; Immunoblotting; Immunohistochemistry; Indoles; Isoleucine; Male; Organ Specificity; Piperidines; Pyrazines; Rats; Sitagliptin Phosphate; Species Specificity; Spermatozoa; Testis; Triazoles | 2009 |
Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cost Savings; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Emergency Service, Hospital; Exenatide; Female; Glycated Hemoglobin; Health Care Costs; Health Services Research; Humans; Hypoglycemic Agents; Insurance Claim Review; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Regression Analysis; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States; Venoms | 2009 |
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2009 |
Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone?
Topics: Amiodarone; Contraindications; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pyrazines; Renal Insufficiency; Rhabdomyolysis; Simvastatin; Sitagliptin Phosphate; Triazoles; United Kingdom; United States | 2009 |
Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.
Topics: Aged; Anticholesteremic Agents; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lovastatin; Pyrazines; Rhabdomyolysis; Sitagliptin Phosphate; Triazoles | 2009 |
Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2009 |
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
Topics: Adolescent; Adult; Databases, Factual; Exenatide; Female; Glyburide; Humans; Hypoglycemic Agents; Insurance, Health; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Safety; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult | 2009 |
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.
Topics: Amyloid; Animals; Animals, Genetically Modified; Arginine; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Clamp Technique; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Islet Amyloid Polypeptide; Islets of Langerhans; Metformin; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles | 2009 |
I read about a new drug for diabetes called Januvia. Should I be interested in it?
Topics: Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles; Weight Gain | 2009 |
CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia.
Topics: Adolescent; Cell Membrane; Child; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Kinetics; Lymphocyte Activation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Reference Values; Sitagliptin Phosphate; Triazoles; Young Adult | 2009 |
Highly efficient asymmetric synthesis of sitagliptin.
Topics: Dipeptidyl-Peptidase IV Inhibitors; Green Chemistry Technology; Hydrogenation; Pyrazines; Sitagliptin Phosphate; Stereoisomerism; Triazoles | 2009 |
Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors.
Topics: Animals; Benzimidazoles; Chemistry, Pharmaceutical; Crystallography, X-Ray; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Drug Design; Glucagon-Like Peptide 1; Humans; Hydrolysis; Imidazoles; Inhibitory Concentration 50; Macaca mulatta; Mice; Piperidines; Pyrazines; Pyridines; Rats; Sitagliptin Phosphate; Triazoles | 2009 |
By the way, doctor. I've had type 2 diabetes for 12 years; I'm now 81. I take metformin plus Januvia. My doctor has never suggested that I monitor myself on a daily basis with a meter. My hemoglobin A1c has been creeping up and is now at 7. Should I
Topics: Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Topics: Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Drug Synergism; Europe; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Sulfonylurea Compounds; Triazoles | 2009 |
Sitagliptin: serious allergies. Risks greater than benefits.
Topics: Drug Hypersensitivity; Europe; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Body Composition; Body Weight; Clozapine; Dibenzothiazepines; Dietary Fats; Disease Models, Animal; Eating; Exenatide; Food Preferences; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Peptides; Pyrazines; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic.
Topics: Ambulatory Care Facilities; Cohort Studies; Cross-Sectional Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Drug Utilization Review; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney Function Tests; Medication Errors; Pharmacists; Private Sector; Professional Role; Pyrazines; Renal Insufficiency; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States | 2009 |
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Ki-67 Antigen; Lipids; Liver; Male; Mice; Mice, Inbred ICR; Organ Size; Pyrazines; Sitagliptin Phosphate; Triazoles; Triglycerides | 2009 |
Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Topics: Animals; Apoptosis; Blood Glucose; Caspase 3; Cell Line; Cell Proliferation; Cell Survival; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Hypoglycemic Agents; Incretins; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Peptides; Pyrazines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2009 |
Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon.
Topics: Adamantane; Cinnamomum zeylanicum; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2009 |
[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2009 |
The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.
Topics: Animals; Blood Glucose; Cell Proliferation; Cell Survival; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin-Secreting Cells; Mice; Peptides; Pyrazines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
[Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Pyrazines; Reference Values; Sitagliptin Phosphate; Triazoles | 2009 |
[Combination antidiabetic therapy. Better control of blood glucose values].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2009 |
Initial therapy for type 2 diabetes. Examination of a combination approach.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Practice; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nurse Practitioners; Practice Guidelines as Topic; Primary Health Care; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Memory Disorders; Mice; Mice, Transgenic; Motor Activity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Metformin; Models, Theoretical; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.
Topics: Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Peptides; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
Topics: Coronary Artery Disease; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography, Stress; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Myocardial Stunning; Pilot Projects; Pyrazines; Reproducibility of Results; Sitagliptin Phosphate; Triazoles; Ventricular Dysfunction, Left | 2010 |
Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.
Topics: Analysis of Variance; Animals; Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Exenatide; Fat Emulsions, Intravenous; Gene Expression; Glucagon-Like Peptide 1; Glucose; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Peptides; Pyrazines; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Topics: Animals; Cardiovascular System; Coronary Vessels; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gene Deletion; Heart; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Ischemia; Pyrazines; Reference Values; Reperfusion; Sitagliptin Phosphate; Survivors; Triazoles | 2010 |
Elevated hepatic enzymes potentially associated with sitagliptin.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Humans; Liver; Liver Function Tests; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Lipopolysaccharide Receptors; Male; Membrane Proteins; Middle Aged; Monocytes; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
Topics: Animals; Blood Glucose; Blotting, Western; Body Weight; Culture Media; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl-Peptidase IV Inhibitors; Eicosanoids; Glucagon-Like Peptide 1; Hypertrophy, Left Ventricular; Hypoglycemic Agents; In Vitro Techniques; Mice; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Organ Size; Phospholipases A2; Pioglitazone; Prostaglandin-Endoperoxide Synthases; Protective Agents; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2010 |
Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.
Topics: Analysis of Variance; Animals; CD4-Positive T-Lymphocytes; Cell Movement; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Incretins; Lymph Nodes; Mice; Mice, Inbred NOD; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Spleen; T-Lymphocyte Subsets; Thymus Gland; Triazoles | 2010 |
Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.
Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Hypertension; Kidney; Male; Metabolic Syndrome; Proteinuria; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Sitagliptin Phosphate; Triazoles; Vasoconstriction; Vasoconstrictor Agents | 2010 |
New therapeutic options: management strategies to optimize glycemic control.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Therapy, Combination; Energy Intake; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrazines; Sitagliptin Phosphate; Telmisartan; Triazoles | 2010 |
Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Topics: Adult; Age Factors; Aged; Body Mass Index; Body Weight; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insurance Claim Review; Lipids; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sex Factors; Sitagliptin Phosphate; Socioeconomic Factors; Triazoles; Venoms | 2010 |
[New hypoglycemic agents in type 2 diabetes].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2010 |
Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Topics: Administration, Oral; Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Electronic Health Records; Humans; Hyperglycemia; Hypoglycemic Agents; Individuality; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States | 2010 |
Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report.
Topics: Anti-Obesity Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Lactones; Middle Aged; Orlistat; Pancreatitis; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Irbesartan; Pyrazines; Sitagliptin Phosphate; Tetrazoles; Treatment Outcome; Triazoles | 2010 |
Choosing among the incretin agents and why it matters.
Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture.
Topics: Amines; Biocatalysis; Catalytic Domain; Directed Molecular Evolution; Hypoglycemic Agents; Ketones; Models, Molecular; Molecular Structure; Mutagenesis; Protein Conformation; Protein Engineering; Pyrazines; Sitagliptin Phosphate; Solubility; Stereoisomerism; Substrate Specificity; Transaminases; Triazoles | 2010 |
Sitagliptin: too many cases of pancreatitis.
Topics: Acute Disease; Humans; Hypoglycemic Agents; Pancreatitis; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Individualised incretin-based treatment for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Determination of sitagliptinin human plasma using protein precipitation and tandem mass spectrometry.
Topics: Chemical Precipitation; Dipeptidyl-Peptidase IV Inhibitors; Drug Stability; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Least-Squares Analysis; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Sitagliptin Phosphate; Solid Phase Extraction; Tandem Mass Spectrometry; Temperature; Triazoles | 2010 |
Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Hypersensitivity; Female; Glucagon-Like Peptide 1; Humans; Incidence; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States | 2010 |
Biochemistry. Reengineering enzymes.
Topics: Algorithms; Biocatalysis; Catalytic Domain; Chemical Phenomena; Computer Simulation; Directed Molecular Evolution; DNA Shuffling; Enzyme Stability; Enzymes; Mutagenesis; Protein Engineering; Protein Folding; Pyrazines; Sitagliptin Phosphate; Software; Stereoisomerism; Substrate Specificity; Transaminases; Triazoles | 2010 |
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glycated Hemoglobin; Insulin; Insulin Resistance; Interleukin-1beta; Lipids; Male; Oxidative Stress; Pancreas; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2010 |
Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Enalapril; Heart Rate; Hemodynamics; Humans; Metabolic Syndrome; Models, Biological; Peptidyl-Dipeptidase A; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pancreatitis; Peptides; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Sitagliptin in treatment of diabetes complicated by chronic hepatitis C.
Topics: Blood Glucose; Comorbidity; Diabetes Complications; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Female; Hepatitis C, Chronic; Humans; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes.
Topics: Animals; Apoptosis; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA Fragmentation; Female; Glutathione; Glutathione Peroxidase; Kidney; Kidney Diseases; Lipid Peroxidation; Male; Oxidative Stress; Peroxidase; Pyrazines; Rats; Rats, Wistar; Reperfusion Injury; Sitagliptin Phosphate; Superoxide Dismutase; Triazoles; Xanthine Oxidase | 2011 |
Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drinking; Drug Evaluation, Preclinical; Eating; Exenatide; Fatty Liver; Fructose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metabolic Syndrome; Peptides; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters.
Topics: Adenylate Kinase; Animals; Biological Transport; Dogs; Hep G2 Cells; Humans; Kinetics; Metformin; Organic Cation Transporter 1; Phosphorylation; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Health Status; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Acceptance of Health Care; Pyrazines; Sitagliptin Phosphate; Triazoles; United States | 2010 |
Severe leucopenia associated with Sitagliptin use.
Topics: Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Leukopenia; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
[New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2010 |
Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
Topics: Adipocytes; Adipose Tissue; Adiposity; Animals; Anti-Inflammatory Agents; Body Weight; Cytokines; Dipeptidyl-Peptidase IV Inhibitors; Flow Cytometry; Glucose; Glucose Intolerance; Glucose Tolerance Test; Immunohistochemistry; Inflammation; Insulin; Islets of Langerhans; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Neutrophil Infiltration; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles | 2011 |
Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.
Topics: Aging; Animals; Blood Pressure; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Hypertension; Kidney; Kidney Tubules, Proximal; Male; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sitagliptin Phosphate; Sodium-Hydrogen Exchanger 3; Sodium-Hydrogen Exchangers; Triazoles | 2011 |
Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; India; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Statistics, Nonparametric; Triazoles; Triglycerides | 2011 |
Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Dipeptidyl Peptidase 4; Female; Hypoglycemic Agents; In Vitro Techniques; Male; Mice; Mice, Knockout; Obesity; Ovariectomy; Pioglitazone; PPAR gamma; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2011 |
Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.
Topics: Animals; Aorta; Capillaries; Carotid Arteries; Cell Line; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Endothelial Cells; Endothelium, Vascular; Humans; Myocardium; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2011 |
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Lipoproteins; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
Sitagliptin manufacture: a compelling tale of green chemistry, process intensification, and industrial asymmetric catalysis.
Topics: Biocatalysis; Diabetes Mellitus, Type 2; Green Chemistry Technology; Humans; Pyrazines; Ruthenium; Sitagliptin Phosphate; Transaminases; Triazoles | 2011 |
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Topics: Adverse Drug Reaction Reporting Systems; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Odds Ratio; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; United States; United States Food and Drug Administration; Venoms | 2011 |
Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.
Topics: Animals; Caspase 3; ets-Domain Protein Elk-1; Fluorescent Antibody Technique; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Islets of Langerhans; Male; Metformin; Oligonucleotide Array Sequence Analysis; Pyrazines; Rats; Rats, Zucker; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles | 2011 |
Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Feeding Behavior; Glucagon; Glucagon-Like Peptide 1; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2011 |
Inhibition of anaphylaxis like reaction and mast cell activation by Sitagliptin.
Topics: Anaphylaxis; Animals; Cytokines; Dose-Response Relationship, Drug; Histamine Release; Hypersensitivity; Immunoglobulin E; Male; Mast Cells; Mice; Ovalbumin; p-Methoxy-N-methylphenethylamine; Passive Cutaneous Anaphylaxis; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Tumor Necrosis Factor-alpha | 2011 |
Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry.
Topics: Animals; Blood Stains; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Drug Storage; Humans; Hypoglycemic Agents; Lasers, Semiconductor; Metformin; Mice; Mice, Inbred C57BL; Molecular Structure; Pyrazines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sitagliptin Phosphate; Species Specificity; Specimen Handling; Tandem Mass Spectrometry; Temperature; Triazoles | 2011 |
Journal withdraws article after complaints from drug manufacturers.
Topics: Diabetes Mellitus, Type 2; Drug Industry; Editorial Policies; Exenatide; Humans; Hypoglycemic Agents; Incretins; Pancreatitis; Peptides; Periodicals as Topic; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
A case of drug-induced hepatic injury associated with sitagliptin.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Jaundice; Liver; Male; Microscopy, Electron, Transmission; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
A diabetes drug, sitagliptin, also has a potential to prevent diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2011 |
[Incretin enhancer: sitagliptin].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Insulin; Islets of Langerhans; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Obesity; Pancreas; Pancreas, Exocrine; Pyrazines; Sitagliptin Phosphate; Telmisartan; Triazoles | 2011 |
Merging the best of two worlds: artificial metalloenzymes for enantioselective catalysis.
Topics: Catalysis; Coordination Complexes; DNA; Enzymes; Metalloproteins; Models, Molecular; Oxidation-Reduction; Pyrazines; Ruthenium; Sitagliptin Phosphate; Stereoisomerism; Triazoles | 2011 |
Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes.
Topics: Administration, Oral; Animals; Apoptosis; Arachidonic Acid; Diabetes Mellitus; Dietary Carbohydrates; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucokinase; Glucose; Haploinsufficiency; Insulin-Secreting Cells; Linoleic Acid; Male; Mice; Pyrazines; Receptors, Glucagon; Signal Transduction; Sitagliptin Phosphate; Sucrose; Triazoles | 2011 |
DPP-IV inhibitor may affect spermatogenesis.
Topics: Adult; Amoxapine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ejaculation; Humans; Male; Neurotransmitter Uptake Inhibitors; Pyrazines; Semen Analysis; Sitagliptin Phosphate; Spermatogenesis; Triazoles | 2011 |
Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product.
Topics: Chromatography, Liquid; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Indicators and Reagents; Metformin; Pharmaceutical Preparations; Pyrazines; Quality Control; Reproducibility of Results; Sitagliptin Phosphate; Triazoles | 2011 |
Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Topics: Adult; Animals; Blood Glucose; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrazines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Vagus Nerve | 2011 |
Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report.
Topics: Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Middle Aged; Organ Transplantation; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
GLP-1-based therapies: the dilemma of uncertainty.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; Uncertainty; Venoms | 2011 |
Development of a molecularly imprinted polymer for selective extraction followed by liquid chromatographic determination of sitagliptin in rat plasma and urine.
Topics: Adsorption; Animals; Blood Chemical Analysis; Calibration; Chemical Fractionation; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kinetics; Limit of Detection; Linear Models; Molecular Imprinting; Polymers; Pyrazines; Rats; Reproducibility of Results; Sitagliptin Phosphate; Solvents; Triazoles; Urinalysis | 2011 |
Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.
Topics: Animals; Apoptosis; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucagon-Like Peptide 1; Insulin-Secreting Cells; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred C57BL; Pancreatectomy; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation.
Topics: Animals; Carcinoma, Squamous Cell; Cells, Cultured; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Epidermis; Epithelial Cells; Fibroblasts; Gene Expression; Humans; Interleukin-1alpha; Keratinocytes; Male; MAP Kinase Kinase 1; Mice; Mice, Inbred C57BL; Mice, Transgenic; Papilloma; Pyrazines; Sitagliptin Phosphate; Skin Neoplasms; Stromal Cells; Triazoles; Up-Regulation | 2012 |
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2011 |
Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?
Topics: Aged; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Triazoles | 2011 |
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.
Topics: Adamantane; Amides; Blood Proteins; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dibenzocycloheptenes; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Humans; Inhibitory Concentration 50; Kinetics; Nitriles; Protein Binding; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Tetrazoles; Time Factors; Triazoles; Ultracentrifugation; Vildagliptin | 2011 |
Effects of DPP-4 inhibition on cardiac metabolism and function in mice.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Body Weight; CD36 Antigens; Cell Membrane; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fibrosis; Glucose Tolerance Test; Glucose Transporter Type 4; Glycation End Products, Advanced; Guanine; Heart; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Phosphorylation; Protein Transport; Pyrazines; Sitagliptin Phosphate; Triazoles; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; United Kingdom; Young Adult | 2012 |
Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells.
Topics: Gene Expression Regulation; Glucagon-Like Peptide 1; Glycation End Products, Advanced; Human Umbilical Vein Endothelial Cells; Humans; Nitric Oxide Synthase Type III; Protective Agents; Pyrazines; Reactive Oxygen Species; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Serum Albumin, Bovine; Sitagliptin Phosphate; Triazoles | 2011 |
Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Middle Aged; Pruritus; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2012 |
Evaluation of the interaction between sitagliptin and cyclodextrin derivatives by capillary electrophoresis and nuclear magnetic resonance spectroscopy.
Topics: Cyclodextrins; Electrophoresis, Capillary; Fluorine; Hydrogen-Ion Concentration; Nuclear Magnetic Resonance, Biomolecular; Pyrazines; Sitagliptin Phosphate; Stereoisomerism; Temperature; Triazoles | 2011 |
Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction.
Topics: Aged; Atorvastatin; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Male; Pyrazines; Pyrroles; Rhabdomyolysis; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
[Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry].
Topics: Animals; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Pyrazines; Rats; Sitagliptin Phosphate; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2011 |
Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure.
Topics: Animals; Calmodulin; Cardiac Pacing, Artificial; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Glomerular Filtration Rate; Heart Failure; Heart Rate; Hemodynamics; Interleukin-6; Natriuretic Peptide, Brain; Pyrazines; Sitagliptin Phosphate; Sodium-Calcium Exchanger; Swine; Triazoles | 2012 |
The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Psoriasis; Pyrazines; Sitagliptin Phosphate; T-Lymphocytes; Treatment Outcome; Triazoles | 2012 |
Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
Topics: Exenatide; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation.
Topics: Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Kidney Transplantation; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Sitagliptin and simvastatin (juvisync).
Topics: Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Costs; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Simvastatin; Sitagliptin Phosphate; Triazoles | 2011 |
Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning.
Topics: Animals; Bone Marrow Transplantation; Dipeptidyl-Peptidase IV Inhibitors; Female; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Oligopeptides; Pyrazines; Sitagliptin Phosphate; Transplantation Conditioning; Transplantation, Homologous; Triazoles | 2012 |
Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Fasting; Glucose Tolerance Test; Homeostasis; Insulin-Secreting Cells; Ki-67 Antigen; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Organ Size; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2011 |
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Heart; Humans; Kidney Failure, Chronic; Linagliptin; Myocardium; Natriuretic Peptide, Brain; Nephrectomy; Piperidines; Purines; Pyrazines; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles; Uracil; Uremia | 2011 |
Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.
Topics: Animals; Apoptosis; Blood-Retinal Barrier; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Immunohistochemistry; In Situ Nick-End Labeling; Male; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2012 |
Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Triazoles | 2012 |
Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Japan; Life Style; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease Susceptibility; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infections; Liraglutide; Pancreatitis; Pharmacovigilance; Pioglitazone; Pyrazines; Risk Assessment; Safety-Based Drug Withdrawals; Sitagliptin Phosphate; Species Specificity; Thiazolidinediones; Thyroid Neoplasms; Triazoles; Urinary Bladder Neoplasms | 2012 |
Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Topics: Animals; Animals, Newborn; Cell Line; Cyclic AMP; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Exenatide; Extracellular Signal-Regulated MAP Kinases; Glucagon-Like Peptide 1; Humans; Ionomycin; Mice; Molecular Structure; Peptides; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Insulin; Kidney Glomerulus; Lipid Peroxidation; Lipids; Male; Obesity; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Cells, Cultured; Coronary Artery Disease; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection.
Topics: Animals; Apolipoproteins E; Coronary Artery Disease; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures.
Topics: Alzheimer Disease; Animals; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Male; Neurons; Phosphorylation; Primary Cell Culture; Pyrazines; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Sitagliptin Phosphate; tau Proteins; Triazoles | 2012 |
Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
Topics: Acute Kidney Injury; Adolescent; Adult; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Labeling; Exenatide; Female; Humans; Incidence; Male; Middle Aged; Peptides; Proportional Hazards Models; Pyrazines; Retrospective Studies; Risk Assessment; Sitagliptin Phosphate; Triazoles; Venoms; Young Adult | 2012 |
Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice.
Topics: Animals; Apolipoprotein B-100; Biological Transport; Biomarkers; Blood Glucose; Cholesterol; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Intestinal Absorption; Lipoproteins, HDL; Macrophages; Male; Metformin; Mice; Mice, Obese; Mice, Transgenic; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
Topics: Allylamine; Animals; Anticholesteremic Agents; Apoptosis; Bile Acids and Salts; Blood Glucose; Body Weight; Cell Proliferation; Cell Size; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Diet; Drug Synergism; Fluorescent Antibody Technique; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; In Situ Nick-End Labeling; Insulin; Insulin-Secreting Cells; Ki-67 Antigen; Male; Postprandial Period; Pyrazines; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; RNA, Messenger; Sitagliptin Phosphate; Triazoles | 2012 |
Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Extremities; Female; Humans; Middle Aged; Psoriasis; Pyrazines; Sitagliptin Phosphate; Torso; Triazoles | 2012 |
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
Topics: Adult; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Humans; Hypoglycemic Agents; Long-Term Care; Male; Markov Chains; Middle Aged; Models, Theoretical; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; United States; Venoms | 2012 |
Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study.
Topics: Adult; Aged; Body Mass Index; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Overweight; Pyrazines; Regression Analysis; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Weight Loss | 2012 |
Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Male; Photosensitivity Disorders; Protective Clothing; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
[Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
Topics: Adamantane; Algorithms; Animals; Artifacts; Cloning, Molecular; Dipeptidases; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Indicators and Reagents; Kinetics; Macaca fascicularis; Nitriles; Protein Binding; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Species Specificity; Triazoles; Vildagliptin | 2012 |
Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.
Topics: Adiponectin; Administration, Oral; Animals; Blood Glucose; C-Reactive Protein; Carotid Arteries; Carotid Artery Injuries; Chemokine CCL2; Coronary Restenosis; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Plasminogen Activator Inhibitor 1; Pyrazines; Rats; Rats, Inbred OLETF; Sitagliptin Phosphate; Triazoles; Tumor Necrosis Factor-alpha; Tunica Intima | 2012 |
Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Humans; Islets of Langerhans; Losartan; Male; Mice; Pyrazines; Regeneration; Sitagliptin Phosphate; Stem Cells; Triazoles | 2012 |
Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Topics: Administration, Oral; Chromatography, Liquid; Dipeptidyl-Peptidase IV Inhibitors; Drug Stability; Humans; Least-Squares Analysis; Liquid-Liquid Extraction; Male; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; Sitagliptin Phosphate; Tandem Mass Spectrometry; Triazoles | 2013 |
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptides; Drinking; Eating; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Immunohistochemistry; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy.
Topics: Aged; Blood Glucose; Blood Pressure; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Weight Gain | 2012 |
Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Immunohistochemistry; Lipid Metabolism; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Choosing a blood-glucose-lowering agent after metformin.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Topics: Adult; Aged; Aged, 80 and over; Calibration; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Time Factors; Triazoles | 2012 |
Sitagliptin exerts anti-inflammatory and anti-allergic effects in ovalbumin-induced murine model of allergic airway disease.
Topics: Animals; Anti-Allergic Agents; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Inflammation; Lung; Male; Mice; Nitric Oxide Synthase Type II; Ovalbumin; Pyrazines; RNA, Messenger; Sitagliptin Phosphate; Triazoles | 2012 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Association between sitagliptin adherence and self-monitoring of blood glucose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; Child; Computer Simulation; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Logistic Models; Male; Medication Adherence; Metformin; Middle Aged; Odds Ratio; Predictive Value of Tests; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; United States; Young Adult | 2012 |
Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system.
Topics: Acetates; Anthraquinones; Azithromycin; Benzhydryl Compounds; Cinacalcet; Cloxacillin; Cresols; Cyclopropanes; Female; Fluorobenzenes; Humans; Hydrochlorothiazide; Losartan; Male; Metformin; Naphthalenes; Phenylpropanolamine; Piroxicam; Pyrazines; Pyrimidines; Quinolines; Rosuvastatin Calcium; Saliva; Sitagliptin Phosphate; Sulfides; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Triazoles | 2012 |
Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells.
Topics: Animals; Chemokine CXCL12; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endothelial Cells; Glucagon-Like Peptide 1; Hindlimb; Ischemia; Male; Mice; Mice, Inbred ICR; Mice, Transgenic; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Platelet Endothelial Cell Adhesion Molecule-1; Pyrazines; Sitagliptin Phosphate; Stem Cells; Triazoles | 2012 |
Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin.
Topics: Animals; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Liver; Male; Obesity; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles | 2012 |
Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells.
Topics: Animals; Arginine; Cell Proliferation; Cells, Cultured; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glomerular Mesangium; Glucagon-Like Peptide 1; Male; Models, Animal; Muscle, Smooth, Vascular; Neuropeptide Y; Peptide Fragments; Peptide YY; Proline; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sitagliptin Phosphate; Thymidine; Triazoles | 2012 |
Sitagliptin-associated angioedema.
Topics: Angioedema; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Markov Chains; Metformin; Outcome Assessment, Health Care; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.
Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Japan; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2012 |
Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.
Topics: Alleles; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Genetic Predisposition to Disease; HLA-DRB1 Chains; Humans; Middle Aged; Pyrazines; Rheumatoid Factor; Sitagliptin Phosphate; Triazoles | 2012 |
Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Topics: Aged; Aged, 80 and over; Animals; Blood Pressure; Cells, Cultured; Cyclic AMP; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endothelium, Vascular; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypertension; In Vitro Techniques; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Nitric Oxide; Peptides; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Glucagon; Regional Blood Flow; Renal Artery; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
Mechanism of action of DPP-4 inhibitors--new insights.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.
Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Female; Hepatocytes; Humans; Male; Middle Aged; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.
Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Obesity; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Satiation; Sitagliptin Phosphate; Triazoles | 2012 |
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Drug Evaluation; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Inflammation; Liraglutide; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pioglitazone; Platelet Count; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2012 |
Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Chi-Square Distribution; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Utilization; Drug Utilization Review; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Logistic Models; Male; Middle Aged; Patient Safety; Practice Patterns, Physicians'; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Triazoles | 2012 |
Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glucose Intolerance; Insulin; Islets of Langerhans; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Streptozocin; Triazoles; Xanthones | 2012 |
Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.
Topics: Adult; Aged; Blood Platelets; Blood Proteins; Calcium; Case-Control Studies; Cells, Cultured; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazines; Sitagliptin Phosphate; Thrombin; Triazoles; Tyrosine | 2012 |
[Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction].
Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Kidney Failure, Chronic; Metabolic Syndrome; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sitagliptin Phosphate; Survival Rate; Triazoles | 2012 |
DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Heart; Myocardial Infarction; Pyrazines; Rats; Rats, Inbred F344; Sitagliptin Phosphate; Streptozocin; Triazoles; Ventricular Remodeling | 2013 |
Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Humans; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Nude; Nateglinide; Peptides; Phenylalanine; Pyrazines; Sitagliptin Phosphate; Specific Pathogen-Free Organisms; Triazoles; Venoms | 2013 |
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Adenoma; Anatomy, Cross-Sectional; Animals; Chlorocebus aethiops; Colon; Colonic Neoplasms; COS Cells; Cyclic AMP; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide-2 Receptor; Hypoglycemic Agents; Intestinal Mucosa; Intestine, Small; Liraglutide; Mice; Mice, Inbred C57BL; Organ Size; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Transfection; Triazoles; Venoms | 2012 |
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin | 2012 |
Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy.
Topics: Adult; Blood Glucose; Cardiomyopathy, Dilated; Dipeptidyl-Peptidase IV Inhibitors; Female; Fluorodeoxyglucose F18; Humans; Insulin Resistance; Male; Middle Aged; Myocardium; Pyrazines; Sitagliptin Phosphate; Statistics as Topic; Statistics, Nonparametric; Triazoles | 2012 |
Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose; Glucose Transporter Type 4; Heart; Homeostasis; Intracellular Space; Male; Muscle, Skeletal; Myocytes, Cardiac; Phosphorylation; Protein Transport; Pyrazines; Rats; Rats, Inbred SHR; RNA, Messenger; Signal Transduction; Sitagliptin Phosphate; Triazoles; Up-Regulation | 2013 |
Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates.
Topics: Aged; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Blood Coagulation Factors; Bradykinin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypertension; Laryngeal Diseases; Male; Perindopril; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Dipeptidyl peptidase IV inhibitor improves the salivary gland histology of spontaneously diabetic mice.
Topics: Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Extracellular Matrix; Female; Homeostasis; Hypoglycemic Agents; Mice; Mice, Inbred NOD; Microscopy, Polarization; Pyrazines; Salivary Glands; Sitagliptin Phosphate; Triazoles | 2013 |
Cycloart-23-ene-3β, 25-diol stimulates GLP-1 (7-36) amide secretion in streptozotocin-nicotinamide induced diabetic Sprague Dawley rats: a mechanistic approach.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drinking; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucose Tolerance Test; Insulin; Male; Molecular Docking Simulation; Niacinamide; Oxidative Stress; Pancreas; Peptide Fragments; Protein Conformation; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Time Factors; Triazoles; Triterpenes | 2013 |
Sitagliptin successfully ameliorates glycemic control in Werner syndrome with diabetes.
Topics: Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Werner Syndrome | 2012 |
Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin.
Topics: Acute Kidney Injury; Aged; Back; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ear; Edema; Eosinophilia; Exanthema; Female; Glucocorticoids; Humans; Prednisone; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells.
Topics: Cell Line; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endothelial Cells; Gene Expression Regulation; Glucagon-Like Peptide 1; Humans; Intercellular Adhesion Molecule-1; NF-kappa B; Nuclear Receptor Subfamily 4, Group A, Member 1; Plasminogen Activator Inhibitor 1; Promoter Regions, Genetic; Pyrazines; Sitagliptin Phosphate; Transcriptional Activation; Triazoles; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2013 |
Design and formulation of mucoadhesive microspheres of sitagliptin.
Topics: Animals; Chemistry, Pharmaceutical; Drug Design; Hypoglycemic Agents; Microscopy, Electron, Scanning; Microspheres; Pyrazines; Rabbits; Rats; Sitagliptin Phosphate; Triazoles | 2013 |
Development of a gas chromatography-mass spectrometry method for the analysis of sitagliptin in human urine.
Topics: Female; Gas Chromatography-Mass Spectrometry; Humans; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure.
Topics: Adult; Area Under Curve; Biomarkers; Bone Resorption; Collagen Type I; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glucagon-Like Peptide 2; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Peptide Fragments; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects.
Topics: Adult; Blood Glucose; Dietary Fats; Dietary Proteins; Dipeptidyl-Peptidase IV Inhibitors; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Micronutrients; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor.
Topics: Acids, Heterocyclic; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Oxadiazoles; Pyrazines; Receptors, G-Protein-Coupled; Regeneration; Sitagliptin Phosphate; Triazoles | 2013 |
Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Chi-Square Distribution; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Inflammation Mediators; Linear Models; Logistic Models; Male; Manometry; Middle Aged; Multivariate Analysis; Odds Ratio; Peripheral Arterial Disease; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Dipeptidyl peptidase-4 inhibitors--emerging player for vascular protection.
Topics: Anti-Inflammatory Agents; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Male; Peripheral Arterial Disease; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Pilot Projects; Postprandial Period; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Effects of sitagliptin beyond glycemic control: focus on quality of life.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycemic Index; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrazines; Quality of Life; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Topics: Acute Disease; Adolescent; Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Hospitalization; Humans; Logistic Models; Male; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
GLP-1 based agents and acute pancreatitis : drug safety falls victim to the three monkey paradigm.
Topics: Acute Disease; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metaphor; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2013 |
Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
Topics: Acute Disease; Animals; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Exenatide; Humans; Hypoglycemic Agents; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
DPP4 inhibitor-induced polyarthritis: a report of three cases.
Topics: Adamantane; Arthritis; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Colon; Diabetes Mellitus, Experimental; Drinking; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Glutamine; Glycated Hemoglobin; Insulin; Lipid Metabolism; Male; Molecular Docking Simulation; Niacinamide; Oxidative Stress; Pancreas; Peptide Fragments; Protein Conformation; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles | 2013 |
Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats.
Topics: Animals; Becaplermin; Cell Proliferation; Collagen; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Gene Expression Regulation; Hepatic Stellate Cells; Liver Cirrhosis, Experimental; Male; Phosphorylation; Proto-Oncogene Proteins c-sis; Pyrazines; Rats; Rats, Inbred F344; Sitagliptin Phosphate; Swine; Transforming Growth Factor beta1; Triazoles | 2014 |
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiotonic Agents; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart; Heart Rate; Insulin; Insulin Resistance; Male; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria, Heart; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Sitagliptin--another option for managing type 2 diabetes in dialysis patients?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Topics: Adamantane; Catalytic Domain; Crystallography, X-Ray; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Multiprotein Complexes; Nitriles; Oligopeptides; Piperidines; Protein Binding; Protein Interaction Mapping; Pyrazines; Pyrazoles; Pyrrolidines; Serine; Sitagliptin Phosphate; Structure-Activity Relationship; Thiazolidines; Triazoles; Uracil; Vildagliptin; X-Ray Diffraction | 2013 |
Pharmacokinetic-pharmacodynamic modelling of biomarker response to sitagliptin in healthy volunteers.
Topics: Adult; Biomarkers; Blood Glucose; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Models, Biological; Pyrazines; Reproducibility of Results; Sitagliptin Phosphate; Triazoles; Young Adult | 2013 |
Pancreatitis associated with incretin-based therapies.
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Incretins; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis.
Topics: Animals; Antipsychotic Agents; Apomorphine; Disease Models, Animal; Dopamine Agonists; Glucagon-Like Peptide 1; Liraglutide; Male; Mice; Psychotic Disorders; Pyrazines; Sitagliptin Phosphate; Statistics, Nonparametric; Triazoles | 2013 |
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
Topics: Adenoma; Adolescent; Adult; Aged; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hyperplasia; Incretins; Insulin-Secreting Cells; Male; Middle Aged; Neuroendocrine Tumors; Organ Size; Pancreas; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Length of Stay; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Pyrazines; Retrospective Studies; Secondary Prevention; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Substitution; Glucagon-Like Peptide 1; Glycemic Index; Health Care Costs; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Failure; Triazoles; United States | 2013 |
Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.
Topics: Adrenocorticotropic Hormone; Central Nervous System Cysts; Delayed-Action Preparations; Dipeptidyl-Peptidase IV Inhibitors; Female; Growth Hormone-Releasing Hormone; Humans; Hyperglycemia; Hyperpigmentation; Middle Aged; Nelson Syndrome; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Somatostatin; Treatment Outcome; Triazoles | 2013 |
Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
Topics: Alanine Transaminase; Animals; Blood Glucose; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Female; Insulin; Insulin Resistance; Liver; Non-alcoholic Fatty Liver Disease; Obesity; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Triglycerides | 2013 |
Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione.
Topics: Absorptiometry, Photon; Animals; Bone Density; Disease Progression; Estrogens; Female; Femur; Humans; Hypoglycemic Agents; Lumbar Vertebrae; Ovariectomy; Pyrazines; Rats; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Micelle-enhanced spectrofluorimetric method for determination of sitagliptin and identification of potential alkaline degradation products using LC-MS.
Topics: Alkalies; Chromatography, Liquid; Hypoglycemic Agents; Limit of Detection; Mass Spectrometry; Micelles; Pyrazines; Sitagliptin Phosphate; Spectrometry, Fluorescence; Triazoles | 2014 |
Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database.
Topics: Administration, Oral; Adult; Age Distribution; Diabetes Mellitus, Type 2; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; United States | 2013 |
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
Topics: Adamantane; Animals; Behavior, Animal; Brain; Cognition Disorders; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Insulin Resistance; Male; Maze Learning; Memory; Memory Disorders; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds.
Topics: Adamantane; Diabetes Mellitus; Dipeptides; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Linagliptin; Pancreatitis; Purines; Pyrazines; Quinazolines; Sitagliptin Phosphate; Triazoles; United States | 2013 |
Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
Topics: Comparative Effectiveness Research; Confounding Factors, Epidemiologic; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypoglycemic Agents; Insurance, Health; Male; Middle Aged; Myocardial Ischemia; Practice Guidelines as Topic; Propensity Score; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; United States | 2013 |
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney.
Topics: Acute Kidney Injury; Animals; Dipeptidyl-Peptidase IV Inhibitors; Forkhead Box Protein O3; Forkhead Transcription Factors; Kidney; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles | 2013 |
The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cell Survival; Cytokines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Inverse Agonism; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Linagliptin; Palmitic Acid; Peptide Fragments; Protein Stability; Purines; Pyrazines; Quinazolines; Recombinant Proteins; Sitagliptin Phosphate; Tissue Culture Techniques; Triazoles | 2013 |
Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.
Topics: 1,2-Dimethylhydrazine; Animals; Body Weight; Carcinogenesis; Colonic Neoplasms; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Intestinal Mucosa; Intestines; Male; Mucins; Pyrazines; Random Allocation; Rats; Rats, Inbred F344; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles | 2013 |
Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction.
Topics: Adamantane; Animals; Cell Survival; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Heart; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
[Diabetes treatment in patients with chronic kidney disease].
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Kidney Function Tests; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.
Topics: Animals; C-Peptide; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Streptozocin; Treatment Outcome; Triazoles; Umbilical Cord | 2014 |
The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Ion Channels; Male; Mice; Mice, Inbred C57BL; Mitochondrial Proteins; Obesity; PPAR gamma; Pyrazines; Sitagliptin Phosphate; Triazoles; Uncoupling Protein 1 | 2013 |
Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Exenatide; Female; Health Care Costs; Humans; Hypoglycemic Agents; Linear Models; Male; Medicare Part D; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult | 2013 |
Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan.
Topics: Aged; Cohort Studies; Female; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Japan; Logistic Models; Male; Middle Aged; Patient Safety; Practice Patterns, Physicians'; Propensity Score; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hypoglycemic Agents; Inflammation; Logistic Models; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Hemizygote; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Male; Metformin; Mice; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Pancreatitis; Plaque, Amyloid; Pyrazines; Random Allocation; Recombinant Proteins; Sitagliptin Phosphate; Time Factors; Triazoles | 2013 |
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Nitriles; Pyrazines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Sitagliptin therapy enhances the number of circulating angiogenic cells and angiogenesis-evaluations in vitro and in the rat critical limb ischemia model.
Topics: Adipose Tissue; Animals; Arteries; Biomarkers; Cell Movement; Disease Models, Animal; Endothelial Cells; Hindlimb; Ischemia; Male; Neovascularization, Physiologic; Pyrazines; Rats; Rats, Inbred F344; Regional Blood Flow; Sitagliptin Phosphate; Stem Cells; Triazoles | 2013 |
Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study.
Topics: Aged; Blood Glucose; Chromosome Aberrations; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Micronuclei, Chromosome-Defective; Middle Aged; Pilot Projects; Pioglitazone; Pyrazines; Rosiglitazone; Sister Chromatid Exchange; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms | 2014 |
Sitagliptin improves postprandial hyperglycemia by inhibiting glucagon secretion in Werner syndrome with diabetes.
Topics: Diabetes Mellitus; Female; Glucagon; Humans; Hyperglycemia; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Werner Syndrome | 2013 |
The effects of DPP-IV inhibition in NOD mice with overt diabetes.
Topics: Animals; Diabetes Mellitus, Type 1; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Islets of Langerhans; Lymph Nodes; Mice; Mice, Inbred NOD; Pyrazines; Sitagliptin Phosphate; Spleen; T-Lymphocyte Subsets; Time Factors; Triazoles | 2013 |
Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure.
Topics: Adult; Aged; Animals; Apoptosis; Biomarkers; Case-Control Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Glucagon-Like Peptide 1; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Pulmonary Edema; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Up-Regulation; Ventricular Function, Left; Ventricular Remodeling | 2013 |
An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
Topics: Adolescent; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hyperplasia; Hypoglycemic Agents; Incretins; Male; Middle Aged; Models, Statistical; Pancreas; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Tissue Banks; Triazoles; Venoms; Young Adult | 2013 |
Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Arthritis; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.
Topics: Animals; Binding Sites; Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucose Tolerance Test; Molecular Docking Simulation; Phenylalanine; Protein Binding; Protein Structure, Tertiary; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Structure-Activity Relationship; Triazoles | 2013 |
[Excellence in continuous research. MMW medication award for sitagliptin].
Topics: Awards and Prizes; Biomedical Research; Germany; Humans; Hypoglycemic Agents; Periodicals as Topic; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Sitagliptin: results from clinical practice.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes.
Topics: Action Potentials; Animals; Blood Pressure; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhibitors; Electrocardiography; Heart Ventricles; Hypertension; Inflammation; Interleukin-6; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor for Advanced Glycation End Products; Receptor, Angiotensin, Type 1; Receptors, Immunologic; Sitagliptin Phosphate; Triazoles; Tumor Necrosis Factor-alpha | 2013 |
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Topics: Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2014 |
Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley rats.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Colon; Diabetes Mellitus, Experimental; Drinking Behavior; Feeding Behavior; Glucagon-Like Peptide 1; Glutamine; Glycated Hemoglobin; Insulin; Lipid Metabolism; Male; Niacinamide; Oxidative Stress; Pancreas; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Staining and Labeling; Streptozocin; Triazoles; Triterpenes | 2013 |
Precolumn o-phthalaldehyde-N-acetyl-L-cysteine derivatization followed by RP-HPLC separation and fluorescence detection of sitagliptin enantiomers in rat plasma.
Topics: Acetylcysteine; Animals; Chromatography, High Pressure Liquid; Drug Stability; Fluorescent Dyes; Limit of Detection; Molecular Structure; o-Phthalaldehyde; Pyrazines; Rats; Sitagliptin Phosphate; Spectrometry, Fluorescence; Time Factors; Triazoles | 2013 |
Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model.
Topics: Animals; Apoptosis; Body Weight; Cardiotonic Agents; Creatine Kinase, MB Form; Disease Models, Animal; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glutathione Peroxidase; Heart; Heart Ventricles; L-Lactate Dehydrogenase; Male; Malondialdehyde; Myocytes, Cardiac; Organ Size; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Reperfusion Injury; Sitagliptin Phosphate; Superoxide Dismutase; Triazoles | 2013 |
A novel data-mining platform leveraging social media to monitor outcomes of Januvia.
Topics: Data Mining; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Social Media; Treatment Outcome; Triazoles | 2013 |
Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.
Topics: Area Under Curve; Cord Blood Stem Cell Transplantation; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Population; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Topics: Adamantane; Animals; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Heart; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitriles; Pyrazines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Glucagon; Severity of Illness Index; Signal Transduction; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction.
Topics: Animals; Biomarkers; Creatinine; Exenatide; Inflammation; Kidney; Male; Oxidative Stress; Peptides; Proteinuria; Pyrazines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reperfusion Injury; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor.
Topics: Animals; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glutathione Peroxidase; Hypertension; Hypertension, Renal; Hypoglycemic Agents; Kidney; Lipid Peroxidation; Male; Nephritis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrazines; Rats; Rats, Wistar; Receptors, Glucagon; Sitagliptin Phosphate; Superoxide Dismutase; Triazoles | 2013 |
First treatment of a child suffering from severe ischemic cardiomyopathy with G-CSF and sitagliptin.
Topics: Cardiomyopathies; Combined Modality Therapy; Dipeptidyl-Peptidase IV Inhibitors; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myocardial Ischemia; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.
Topics: Acetates; Animals; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred ICR; Mice, Obese; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Spiro Compounds; Triazoles | 2014 |
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
Topics: Belgium; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles | 2013 |
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblasts; Fibronectins; Fibrosis; Glucagon-Like Peptide 1; Glucose Intolerance; Hypoglycemic Agents; Insulin; Male; Metformin; Myocardium; Myocytes, Cardiac; PPAR delta; Protein Isoforms; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2013 |
Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1.
Topics: Acetylcholine; Adiponectin; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Hypothalamus; Insulin; Lipids; Male; Memory; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Adiponectin; Sitagliptin Phosphate; Triazoles | 2013 |
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses.
Topics: Adamantane; Adaptive Immunity; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Immunity, Innate; Mice; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; T-Lymphocytes; Triazoles; Vildagliptin | 2014 |
Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress.
Topics: Animals; Cyclooxygenase 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endothelium, Vascular; Exenatide; Gene Expression Regulation; Humans; Hypertension; Ion Channels; Male; Mice; Mitochondria; Mitochondrial Proteins; Models, Biological; Oxidative Stress; Peptides; Pyrazines; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Renal Artery; Sitagliptin Phosphate; Triazoles; Uncoupling Protein 2; Vasoconstriction; Venoms | 2014 |
Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway.
Topics: Animals; Blood Glucose; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endothelial Cells; Glucagon-Like Peptide 1; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Neovascularization, Physiologic; Pyrazines; Regional Blood Flow; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sitagliptin Phosphate; Swine; TOR Serine-Threonine Kinases; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Sitagliptin-induced bilateral Achilles tendinitis.
Topics: Achilles Tendon; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Magnetic Resonance Imaging; Middle Aged; Pyrazines; Sitagliptin Phosphate; Tendinopathy; Triazoles | 2014 |
Intraduodenal milk protein concentrate augments the glycemic and food intake suppressive effects of DPP-IV inhibition.
Topics: Animals; Blood Glucose; Dipeptidyl Peptidase 4; Eating; Glucagon-Like Peptide 1; Hypoglycemic Agents; Male; Milk Proteins; Obesity; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles | 2014 |
Time of effect duration and administration interval for sitagliptin in patients with kidney failure.
Topics: Half-Life; Humans; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Time Factors; Triazoles | 2014 |
DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway.
Topics: Atherosclerosis; Cell Line; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Foam Cells; Humans; Lipoproteins, LDL; Macrophages; Protein Kinase C; Pyrazines; Receptors, Scavenger; Sitagliptin Phosphate; Triazoles | 2014 |
Pharmacoeconomic analysis of DPP-4 inhibitors.
Topics: Adamantane; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats.
Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2014 |
Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diet, High-Fat; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Heart; Heart Function Tests; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocardium; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Keratins; Ki-67 Antigen; Male; Metformin; Pancreas, Exocrine; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2014 |
Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.
Topics: Adamantane; Administration, Oral; Animals; Caco-2 Cells; Crystallography, X-Ray; Cyclization; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Discovery; Enzyme Activation; Humans; Inhibitory Concentration 50; Methylamines; Molecular Structure; Nitriles; Pyrazines; Pyrrolidines; Rats; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Topics: AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pyrazines; Random Allocation; Sitagliptin Phosphate; Triazoles | 2014 |
[Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].
Topics: Acarbose; Administration, Oral; Adverse Drug Reaction Reporting Systems; Benzamides; Biguanides; Data Mining; Databases, Pharmaceutical; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Pyrazines; Risk; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2014 |
Sitagliptin ameliorates lipid profile changes and endothelium dysfunction induced by atherogenic diet in rabbits.
Topics: Animals; Diet, Atherogenic; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; L-Lactate Dehydrogenase; Lipids; Male; Malondialdehyde; NF-kappa B; Nitric Oxide; Pyrazines; Rabbits; Sitagliptin Phosphate; Triazoles | 2014 |
Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: the ASSIST-K study.
Topics: Adult; Asian People; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles | 2014 |
Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes.
Topics: Aged; Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Japan; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
High fat diet and GLP-1 drugs induce pancreatic injury in mice.
Topics: Acute Disease; Animals; Apoptosis; Atrophy; Diet, High-Fat; Exenatide; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Necrosis; Pancreas; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2014 |
Long-term efficacy of glibenclamide and sitagliptin therapy in adult patients with KCNJ11 permanent diabetes.
Topics: Adolescent; Adult; Diabetes Mellitus; DNA; DNA Mutational Analysis; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glyburide; Humans; Hypoglycemic Agents; Mutation; Potassium Channels, Inwardly Rectifying; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles | 2014 |
SGLT2 versus DPP4 inhibitors for type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles | 2013 |
Use of antidiabetic drugs in the U.S., 2003-2012.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Marketing of Health Services; Metformin; Pharmacies; Prescription Drugs; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; United States | 2014 |
Liquid chromatography/electrospray ionisation tandem mass spectrometric study of sitagliptin and its stressed degradation products.
Topics: Chromatography, Liquid; Drug Stability; Pyrazines; Quality Control; Reproducibility of Results; Sitagliptin Phosphate; Solvents; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2014 |
Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects.
Topics: Adult; Animals; Area Under Curve; Blood Glucose; C-Peptide; Diet; Drug Synergism; Drug Therapy, Combination; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Lansoprazole; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate.
Topics: Albuminuria; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Design, synthesis and biological evaluation of novel aminomethyl-piperidones based DPP-IV inhibitors.
Topics: Animals; Catalytic Domain; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Enzyme Activation; Hypoglycemic Agents; Inhibitory Concentration 50; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Piperidones; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Management of a prediabetes case with the DPP-4 inhibitor sitagliptin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Middle Aged; Prediabetic State; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Activation of cAMP signaling attenuates impaired hepatic glucose disposal in aged male p21-activated protein kinase-1 knockout mice.
Topics: Animals; Cells, Cultured; Colforsin; Cyclic AMP; Glucagon-Like Peptide 1; Glucose; Hepatocytes; Liver; Male; Mice; Mice, Knockout; p21-Activated Kinases; Pyrazines; Real-Time Polymerase Chain Reaction; Signal Transduction; Sitagliptin Phosphate; Triazoles | 2014 |
Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin.
Topics: Adolescent; Adult; Allylamine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Anticonvulsants; Antihypertensive Agents; Area Under Curve; Aspirin; Atenolol; Colesevelam Hydrochloride; Dose-Response Relationship, Drug; Drug Interactions; Enalapril; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Phenytoin; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Tissue Distribution; Triazoles; Young Adult | 2014 |
Transcriptome analysis of the hippocampus in novel rat model of febrile seizures.
Topics: Animals; Cell Line, Tumor; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Profiling; Gene Ontology; Gene Regulatory Networks; Hippocampus; Pyrazines; Rats; Rats, Sprague-Dawley; Seizures, Febrile; Sitagliptin Phosphate; Triazoles | 2014 |
Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis.
Topics: Adult; Aged; Cohort Studies; Databases, Factual; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms; Young Adult | 2014 |
Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Topics: Animals; Apoptosis; Biomarkers; Blood-Retinal Barrier; Blotting, Western; Cell Death; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme-Linked Immunosorbent Assay; Immunoenzyme Techniques; Inflammation; Male; Neurons; Pyrazines; Rats; Rats, Wistar; Retina; Sitagliptin Phosphate; Triazoles | 2014 |
Comparative activity of proline-containing dipeptide noopept and inhibitor of dipeptidyl peptidase-4 sitagliptin in a rat model of developing diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Proline; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles | 2014 |
Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A.
Topics: Amino Acid Sequence; Conserved Sequence; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hydrogen Bonding; Hypoglycemic Agents; Ligands; Molecular Dynamics Simulation; Molecular Sequence Data; Oligopeptides; Protein Binding; Protein Processing, Post-Translational; Protein Structure, Secondary; Protein Subunits; Pyrazines; Sitagliptin Phosphate; Surface Properties; Triazoles | 2014 |
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Inflammation; Kidney; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Tumor Necrosis Factor-alpha | 2014 |
Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.
Topics: Adult; Aged; Amylases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipase; Male; Middle Aged; Pancreatitis; Pyrazines; Retrospective Studies; Risk Assessment; Sitagliptin Phosphate; Triazoles | 2013 |
Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation.
Topics: Analysis of Variance; Animals; Aorta; Blotting, Western; Dipeptidyl-Peptidase IV Inhibitors; Epigenesis, Genetic; Fluorescent Antibody Technique; Histones; Metabolic Syndrome; Pyrazines; Rats; Sitagliptin Phosphate; Sucrose; Triazoles; Vasodilation | 2014 |
Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis.
Topics: Animals; Biomarkers; Blotting, Western; Choline Deficiency; Diet; Dipeptidyl-Peptidase IV Inhibitors; Endoplasmic Reticulum Stress; Fatty Liver; Immunoenzyme Techniques; Inflammation; Lipid Peroxidation; Liver Cirrhosis; Male; Methionine; Mice; Mice, Inbred C57BL; NF-kappa B; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sitagliptin Phosphate; Triazoles; Triglycerides | 2014 |
Iatrogenic angioedema associated with ACEi, sitagliptin, and deficiency of 3 enzymes catabolizing bradykinin.
Topics: Amino Acid Metabolism, Inborn Errors; Aminopeptidases; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Drug Interactions; Humans; Iatrogenic Disease; Lisinopril; Lysine Carboxypeptidase; Male; Middle Aged; Peptidyl-Dipeptidase A; Polypharmacy; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Triazoles | 2014 |
Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles | 2014 |
Preliminary study characterizing the use of sitagliptin for glycemic control in healthy Beagle dogs with normal gluco-homeostasis.
Topics: Animals; Area Under Curve; Blood Glucose; Dogs; Gene Expression Regulation; Glucagon-Like Peptide 1; Homeostasis; Hypoglycemic Agents; Insulin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Health Services; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Models, Economic; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Smoking; Sulfonylurea Compounds; Sweden; Triazoles | 2014 |
The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice.
Topics: Acute Kidney Injury; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Dipeptidyl-Peptidase IV Inhibitors; Dyslipidemias; Fibronectins; Kidney; Male; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Sitagliptin Phosphate; Transforming Growth Factor beta1; Triazoles | 2014 |
Adherence to prescribing recommendations made on a provincial formulary.
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Cross-Sectional Studies; Female; Fumarates; Guideline Adherence; Health Policy; Humans; Hypoglycemic Agents; Male; Ontario; Pharmacopoeias as Topic; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway.
Topics: Carrier Proteins; Cell Culture Techniques; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Inflammasomes; Interleukin-1beta; Liraglutide; Macrophages; Nitriles; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphorylation; Protein Kinase C; Pyrazines; Pyrrolidines; Receptors, Glucagon; Signal Transduction; Sitagliptin Phosphate; Tetradecanoylphorbol Acetate; Toll-Like Receptor 4; Triazoles | 2014 |
Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Topics: Animals; Atherosclerosis; Blood Glucose; Carotid Arteries; Chemokine CCL2; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; In Vitro Techniques; Insulin; Linagliptin; Malondialdehyde; NADPH Oxidases; Purines; Pyrazines; Quinazolines; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Vasodilation | 2014 |
DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
Topics: Animals; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Compressive Strength; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Male; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Streptozocin; Stress, Mechanical; Triazoles | 2014 |
Noopept normalizes parameters of the incretin system in rats with experimental diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Insulin; Male; Pancreas; Pyrazines; Rats, Wistar; Sitagliptin Phosphate; Triazoles | 2014 |
Sitagliptin for severe psoriasis.
Topics: Aged; Arthritis, Psoriatic; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
Topics: Administration, Oral; Aged; Algorithms; Biomarkers; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Japan; Male; Proinsulin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Greece; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2014 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
Topics: Adamantane; Adult; Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4.
Topics: Animals; Atrial Natriuretic Factor; Compliance; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Diabetes Mellitus, Experimental; Diastole; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Heart; Heart Ventricles; Male; Mice; Myocytes, Cardiac; Pyrazines; Random Allocation; Sitagliptin Phosphate; Triazoles; Ventricular Dysfunction, Left | 2014 |
Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.
Topics: Animals; Blood Pressure; Blood Pressure Determination; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucagon-Like Peptide 1; Hypertension; Male; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2015 |
Quantitative analysis of sitagliptin using the (19)F-NMR method: a universal technique for fluorinated compound detection.
Topics: Fluorine; Magnetic Resonance Spectroscopy; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts.
Topics: Adenosine; Animals; Heart; Male; Myocardial Infarction; Pyrazines; Rats; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles | 2015 |
Effects of dipeptidyl peptidase IV inhibitor sitagliptin on immunological parameters of lymphocytes in intact animals and animals with experimental autoimmune process.
Topics: Animals; Autoimmune Diseases; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Lymph Nodes; Lymphocytes; Male; Mice, Inbred CBA; Pyrazines; Sitagliptin Phosphate; Spleen; Thymus Gland; Triazoles | 2014 |
Utilisation of the isobole methodology to study dietary peptide-drug and peptide-peptide interactive effects on dipeptidyl peptidase IV (DPP-IV) inhibition.
Topics: Amino Acid Sequence; Animals; Computational Biology; Databases, Protein; Dietary Proteins; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Antagonism; Drug Synergism; Expert Systems; Kinetics; Oligopeptides; Peptide Fragments; Peptides; Pyrazines; Sitagliptin Phosphate; Sus scrofa; Triazoles | 2015 |
Plasma gelsolin levels decrease in diabetic state and increase upon treatment with F-actin depolymerizing versions of gelsolin.
Topics: Actins; Adult; Animals; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Down-Regulation; Female; Gelsolin; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Peptide Fragments; Polymerization; Pyrazines; Recombinant Proteins; Sitagliptin Phosphate; Streptozocin; Time Factors; Triazoles | 2014 |
Sitagliptin and the risk of hospitalization for heart failure: a population-based study.
Topics: Diabetes Mellitus; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Morbidity; Population Surveillance; Propensity Score; Pyrazines; Retrospective Studies; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Taiwan; Triazoles | 2014 |
Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells.
Topics: Acute Disease; Animals; Arterial Occlusive Diseases; Carotid Arteries; Cell Movement; Cell Proliferation; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endothelium, Vascular; Male; Mice; Mice, Inbred C57BL; Pyrazines; Regeneration; Signal Transduction; Sitagliptin Phosphate; Stem Cells; Triazoles; Tunica Intima | 2014 |
A novel data-mining approach leveraging social media to monitor consumer opinion of sitagliptin.
Topics: Attitude to Health; Consumer Behavior; Data Mining; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Information Dissemination; Natural Language Processing; Patient Satisfaction; Public Opinion; Pyrazines; Sitagliptin Phosphate; Social Media; Triazoles; Vocabulary, Controlled | 2015 |
Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia.
Topics: Animals; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endotoxemia; Glucagon-Like Peptide 1; Inflammation; Linagliptin; Lipopolysaccharides; Liraglutide; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Purines; Pyrazines; Quinazolines; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles | 2015 |
Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: implication of the oxidative-inflammatory-apoptotic pathway.
Topics: Animals; Brain Ischemia; Caspase 3; Cytochromes c; Diabetes Complications; Diabetes Mellitus, Experimental; Hippocampus; Hypoglycemic Agents; Interleukin-10; Male; Neuroprotective Agents; Neutrophil Infiltration; Pyrazines; Rats; Rats, Wistar; Reperfusion Injury; Sitagliptin Phosphate; Triazoles | 2015 |
Practical, asymmetric route to sitagliptin and derivatives: development and origin of diastereoselectivity.
Topics: Amides; Fluorides; Hydrogen Bonding; Ligands; Mesylates; Models, Molecular; Molecular Structure; Pyrazines; Sitagliptin Phosphate; Stereoisomerism; Triazoles | 2015 |
Gliptins: bullous pemphigoid.
Topics: Adamantane; Aged; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Male; Nitriles; Pemphigoid, Bullous; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2015 |
A new combination of sitagliptin and furosemide protects against remote myocardial injury induced by renal ischemia/reperfusion in rats.
Topics: Animals; Biomarkers; Caspase 3; Furosemide; Kidney; Male; Myocardial Reperfusion Injury; Myocardium; NF-kappa B; Oxidative Stress; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Tumor Necrosis Factor-alpha | 2015 |
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy.
Topics: Adoptive Transfer; Animals; Cell Line, Tumor; Cell Movement; Chemokine CXCL10; Chemokines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Flow Cytometry; Immunotherapy; Lymphocytes; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neoplasms, Experimental; Pyrazines; Receptors, CXCR3; Sitagliptin Phosphate; Triazoles | 2015 |
Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2015 |
Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
Topics: Adamantane; Administration, Intravenous; Administration, Oral; Animals; Biphenyl Compounds; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Haplorhini; Humans; Nitriles; Piperidines; Prospective Studies; Pyridines; Pyrrolidines; Quinolizines; Rats; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2015 |
A novel therapeutic combination of sitagliptin and melatonin regenerates pancreatic β-cells in mouse and human islets.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Humans; Hypoglycemic Agents; Melatonin; Mice; Pyrazines; Sitagliptin Phosphate; Triazoles | 2022 |